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3 ABSTRACT 
Background 
 
Diabetic retinopathy is the leading cause of acquired visual disability among 
people of working age in all industrialised countries. Established risk factors 
for diabetic retinopathy include the duration of diabetes, glycaemic control, 
blood pressure and dyslipidaemia. However, these risk factors explain less 
than half of the risk for diabetic retinopathy. It is, thus, obvious that a large 
proportion of the risk remains to be explored.  
 
Aim 
 
The aim of the present study was to investigate potential risk factors that 
could affect the development of severe forms of retinopathy in type 1 
diabetes.  
 
Patients and Methods 
 
The study patients were drawn from the large FinnDiane (Finnish Diabetic 
Nephropathy study) database. The FinnDiane study is an observational 
cohort study which since 1997 has collected comprehensive data on patients 
with type 1 diabetes at 92 centers throughout Finland with the aim of 
identifying genetic and environmental risk factors for diabetic complications. 
The patients’ retinopathy status were verified from ophthalmic and medical 
files and fundus photographs when available and graded with the ETDRS-
scale. All patients underwent a thorough clinical characterisation of their 
clinical diabetes status by the attending physician at the participating study 
centers. 
 
Results 
 
Proliferative diabetic retinopathy showed significant familial clustering in 
siblings with type 1 diabetes and the heritability h2 adjusted for conventional 
risk factors suggested a significant genetic contribution to the risk. The 
siblings first affected by type 1 diabetes had a lower risk of proliferative 
retinopathy as compared to the siblings later affected by type 1 diabetes. The 
risk of both proliferative retinopathy and clinically significant macular edema 
were modified by the patient’s age at onset of type 1 diabetes. The patients 
with higher age at onset of type 1 diabetes had a lower risk of proliferative 
retinopathy but conversely, a higher risk of clinically significant macular 
edema. The HbA1c variability was lower in those patients with higher age at 
onset of type 1 diabetes and the patients with lower HbA1c variability had a 
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lower cumulative incidence and risk of laser treatment and proliferative 
retinopathy. 
 
Conclusion 
 
In addition to the conventional risk factors, such as diabetes duration, 
glycaemic control and blood pressure, familial factors, age at onset of type 1 
diabetes and glycaemic profile may explain a significant proportion of the 
risk of severe forms of diabetic retinopathy. 
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4 INTRODUCTION 
DRP (diabetic retinopathy) is the most common microvascular complication 
in type 1 diabetes (1). It was first described by Eduard Jäger in 1855, much 
before the discovery of the pathogenesis of type 1 diabetes itself (2). DRP 
changes were so distinct that they were described only a few years after the 
introduction of the first ophthalmoscope by Hermann von Helmholtz in 
1852. At this time, diabetes was a feared and deadly disease. It was known 
that sugar worsened the condition and that the most effective treatment was 
to put the patients on very strict diets where sugar intake was kept to a 
minimum. In some cases, the harsh diets even caused patients to starve to 
death. In 1869, a German medical student, Paul Langerhans, found that 
within the pancreatic tissue there were clusters of cells which were eventually 
shown to be the insulin producing beta cells (3). In 1889, a German 
physiologist Oskar Minkowski and physician Joseph von Mering showed that 
if the pancreas was removed from a dog, the dog developed diabetes (4). In 
1921, doctors Frederick Banting and John MacLeod, a medical student 
Charles Best and a biochemist Bertram Collip purified insulin from the 
pancreatic extract of cattle and in Toronto, Canada, in January 1922, a 14-
year Leonard Thompson was chosen as the first person with diabetes to 
receive insulin  (5). Soon, the industrial production of insulin made it 
possible to save the lives of thousands of patients with type 1 diabetes. 
However, it immediately became evident that diabetes was not a solved 
problem since patients developed a myriad of other health problems that 
decreased their quality of life and shortened their lifespans.  
Almost a hundred years later, and with greatly improved medical care, the 
risk of co-morbidity is reduced, but it is still very much present and puts a 
considerable burden upon the patients. The sheer number of diabetes 
patients weighs heavily upon the whole society as well. There are roughly 
500 000 diagnosed diabetes patients in Finland (6, 7) and nearly 366 million 
worldwide and, by 2030, this number will have soared to 552 million (8). 
Despite modern medical and surgical treatment, the relative risk of blindness 
in diabetes patients is still five times higher as compared to non-diabetic 
people (9). DRP is the most important preventable and treatable cause of 
blindness among working age people in Finland (10).  
Fortunately, with the advent of modern laser and surgical treatment, very 
few patients become blind, but many more will have low vision as a result of 
diabetes.  Visual impairment has a very significant adverse effect on the 
patients’ quality of life (11). Not only is the quality of life lower, but visual 
impairment can also adversely affect the patients ability to manage their 
diabetes which may, in turn, have a negative impact on the incidence of other 
diabetic complications (11). Although hyperglycaemia is a prerequisite for 
DRP, a considerable proportion of the risk remains unexplained. The 
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individual’s response to hyperglycaemia is likely to be influenced by genetic 
and environmental factors. There are well established risk factors for DRP 
such as the duration of diabetes, hyperglycaemia, dyslipidaemia and elevated 
BP (blood pressure). However, these risk factors explain much less than 50% 
of the risk (12, 13). The key to preventing the co-morbidity lies in the 
knowledge of the risk factors. Therefore, this thesis aims to discover and 
quantitate the contribution of other risk factors for DRP. 
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5 REVIEW OF THE LITERATURE 
5.1 THE DIAGNOSIS OF DIABETES 
Diabetes is a heterogeneous group of metabolic disorders characterised by 
elevated blood glucose concentrations (14). The elevated glucose 
concentrations, i.e. hyperglycaemia, may be caused by either insufficient 
insulin secretion by the β-cells in the pancreatic islets, or deficient biological 
action of insulin in target tissues, or both. Defective insulin action in the 
target tissues may also lead to disturbances in amino acid and lipid 
metabolism. The diagnosis of diabetes is primarily based on the 
measurement of fasting plasma glucose concentrations of ≥ 7.0 mmol/l (15). 
If the diagnosis is based solely on the fasting glucose measurements, roughly 
30% of the patients may be left undiagnosed (15, 16). For this reason, a 75-g 
oral glucose tolerance test to detect the elevated plasma glucose 
concentrations is advisable for high risk patients. In this test, a 2-hour post-
load plasma glucose concentration of at least 11.1 mmol/l is diagnostic of 
diabetes. In patients with the classical symptoms of diabetes (thirst, polyuria, 
weight loss), the diagnosis of diabetes may be confirmed by just one 
measurement of a plasma glucose concentration of at least 11.1 mmol/l. The 
glucose concentrations below this fasting cut-off value but above the normal 
range are referred to as IFG (impaired fasting glycaemia) which encompasses 
values which are above normal but below the diagnostic cut-off for diabetes 
(plasma ≥ 6.1 to <7.0 mmol/l), and if the 75-g oral glucose post-load 
concentration is between 7.8 mmol/l–11.0 mmol/l, it is referred to as IGT 
(impaired glucose tolerance) (15).  According to WHO (World Health 
Organization), HbA1c can be used as a diagnostic test for diabetes providing 
that stringent quality assurance tests are in place and assays are standardised 
to criteria aligned to the international reference values, and there are no 
conditions present which preclude its accurate measurement. An HbA1c of ≥ 
6.5% is recommended as the cut-off point for diagnosing diabetes. However, 
a value of less than 6.5% does not exclude diabetes or IGT as diagnosed by 
using the aforementioned tests (17).  
5.2 DIFFERENT TYPES OF DIABETES 
 
Diabetes has traditionally been classified into type 1 and type 2 diabetes (18) 
although this distinction is often not clinically obvious and many patients 
have typical features of both types (19). Despite the overlap of clinical 
representation, it appears that type 1 and type 2 diabetes are genetically 
distinct disease entities (20).  
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Type 1 diabetes, also known as “insulin dependent” or “juvenile onset” 
diabetes, is characterized by the destruction of the insulin-secretory 
pancreatic β-cells of the islets of Langerhans which usually leads to total 
insulin deficiency. The etiology of human type 1 diabetes remains elusive, but 
it is clear that both genetic and environmental factors are important in 
defining the risk (21). The importance of heritable factors was shown in a 
Finnish twin study in which the proband-wise concordance for monozygotic 
twins was estimated to be ~50% as compared with ~8% for dizygotic twins 
(22). The statistical estimates in the Finnish twin population suggested that 
as much as 88% (95% CI 78–94%) of the phenotypic variance in the liability 
to type 1 diabetes was due to additive genetic effects, and 12% (95% CI 6–
22%) to unique environmental effects  (22). The genetic factors may be 
influenced by a complex interaction of familial factors. It has been noted that 
the risk of diabetes may decrease in larger sibships, but studies have also 
suggested that this risk reduction is modified by an interplay between birth 
order and maternal age at delivery (23, 24). Age at onset and sex may affect 
the transmission of type 1 diabetes from diabetic fathers and mothers to their 
offspring. Young age at onset of diabetes in fathers, but not in mothers has 
been shown to increase the risk of type 1 diabetes in the offspring of diabetic 
parents (25). If there are many siblings with diabetes in the family, those 
siblings that are genetically or environmentally most susceptible to diabetes 
are likely to be the first to manifest type 1 diabetes. Hence, the siblings first 
affected by diabetes are usually younger than the later affected siblings (26-
28). 
Both the animal model and human studies have indicated that an 
autoimmune response to the β-cells of the pancreatic islets occurs in type 1 
diabetes. The outcome of this response is substantially influenced by an 
unknown series of probably random environmental events or developmental 
factors. The autoimmune process, which is to a large degree determined by 
the patient’s genotype, then progresses through a preclinical phase, leading 
to the destruction of the β-cells and a stage of hyperglycaemia resulting from 
the reduced β-cell mass and insulin secretory capacity (20). The greatest 
genetic risk for type 1 diabetes is conferred by specific alleles, genotypes, and 
haplotypes of the HLA class II genes. The highly polymorphic HLA class II 
molecules, the DR and DQ α-β heterodimers, are the central players in the 
susceptibility to type 1 diabetes (29, 30). The mechanisms by which the HLA 
class II molecules confer susceptibility to immune-mediated destruction of 
the pancreatic islets is still not known, but the binding of the key peptides 
from autoantigens to HLA class II molecules in the thymus and in the 
periphery is likely to play an important role. There are currently roughly 50 
non-HLA region loci that also influence the type 1 diabetes risk. Many of the 
assumed functions of the non-HLA genes suggest that the genetic variants at 
these loci act in the adaptive and innate immune systems to initiate, amplify, 
and sustain the β-cell destruction (20).   
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A steady increase in the incidence of type 1 diabetes has been going on 
worldwide (31). Finland has the highest incidence of type 1 diabetes in the 
world, reaching 64.2 per 100 000 people per year in 2005 (32).  From 1980 
to 2005 the overall incidence rate of type 1 diabetes in children under the age 
of 15 years has doubled in Finland. The increase has been the greatest in the 
youngest children under 4 years of age (32). It is not clear why this increase 
has taken place. The proposed theories include distorted immune responses 
due to improved hygiene and decreased number of childhood infections (33). 
Another plausible theory proposes that the increase in body weight is leading 
to the younger onset and, thus, higher incidence of type 1 diabetes (34). High 
birth weight and increased early weight gain have indeed been shown to be 
risk factors for type 1 diabetes (31).  
Type 2 diabetes, also known as “non-insulin dependent” or “adult-onset” 
diabetes, is characterized by insulin resistance in the peripheral tissues and 
an insulin secretory defect of the β-cells. Type 2 diabetes is often associated 
with increasing age, obesity, and sedentary lifestyle (35). Genetic liability is 
also a risk factor for type 2 diabetes. In a Finnish twin study, the heritability 
estimates for type 2 diabetes were 73% in males and 64% in females. In this 
study, only one fifth of the covariance of BMI and type 2 diabetes was due to 
shared genetic influences (36). 
Since the advent of the first genome-wide association studies, the 
knowledge of the genetic susceptibility to type 2 diabetes has increased 
dramatically. The number of susceptibility loci for type 2 diabetes started to 
grow significantly in 2007. The current total is approximately more than 40 
confirmed type 2 diabetes loci. Most of these genetic susceptibility variants 
act by disturbing insulin secretion, rather than insulin action, with inherited 
abnormalities of β -cell function and/or mass as the critical components of 
the progression to type 2 diabetes (35). The incidence of type 2 diabetes has 
been on the rise in Finland, as the number of type 2 diabetes patients using 
antidiabetic medications has risen from 42 000 adults in 1970 to 169 000 
adults in 2006 (7, 37). 
The other subtypes of diabetes are diagnosed less frequently. Of the 
remaining diabetes types, the two most prevalent forms are MODY (maturity 
onset diabetes of the young) and LADA (latent autoimmune diabetes of 
adulthood). Among patients with phenotypic type 2 diabetes, LADA occurs in 
10% of individuals older than 35 years and in 25% below 35 years of age (38). 
MODY-type diabetes is a well described, less common subtype of diabetes 
that consists of several monogenic β-cell disorders and  is estimated to 
account for approximately 1% of all diabetes cases (39). This heterogeneous 
group is characterized by autosomal dominant inheritance, young age of 
onset, usually in the 2nd–4th decade, and continued secretion of insulin. The 
most frequent causes are mutations in genes encoding the transcription 
factors HNF1A (Mody 3) and HNF4A (Mody 1) and GCK enzyme (Mody 2). 
Mutations in a number of other genes can also present with a MODY 
phenotype but these are rare in clinical practice (40).  
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The onset of LADA occurs usually in adult life, and because this form is 
usually not initially insulin-requiring, the patients appear clinically to be 
affected by type 2 diabetes. Such patients probably have the same disease 
process as the patients with type 1 diabetes in that they have a similar HLA-
genetic susceptibility, as well as autoantibodies to islet antigens, low insulin 
secretion, and a higher rate of progression to total insulin dependency (41).  
Gestational diabetes refers to insulin resistance that manifests during 
pregnancy. There has been a steady increase in recent years in this form of 
diabetes as well. The prevalence of gestational diabetes in Finland was 10-
11% between the period from 2004 to 2006 (42). 
There are yet other forms of diabetes, such as secondary diabetes caused 
by insulin deficiency due to pancreatitis, trauma or sometimes even 
pancreatic cancer. Iatrogenic diabetes may occur due to immunosuppressive 
medications, such as glucocorticoids (43) and calcineurin inhibitors 
cyclosporine and tacrolimus (44) . 
5.3 DIABETIC COMPLICATIONS 
The complications of diabetes can be broadly classified as microvascular and 
macrovascular, although a number of complications do not easily fit either 
category, such as the increased risk of Alzheimer’s disease, gingivitis and 
female infertility (Fig.1). Despite modern therapeutics, type 1 diabetes 
continues to be associated with the increased risk of premature death. The 
standardised mortality ratio was 3.6 in patients with diabetes diagnosed 
between 0-14 years of age and 2.8 in the patients with diabetes diagnosed 
between 15-29 years of age (45). The median age of death for type 1 diabetes 
patients in Finland was only 49 years in 2002 (46). Fortunately, the life 
expectancy for type 1 diabetes patients has been steadily improving. The 
results of a 30-year study by the University of Pittsburgh showed that 
patients with type 1 diabetes born after 1965 had a life expectancy of 69 
years, whereas in participants diagnosed 1950–1964 it was only 53 years 
(47). A similar time trend has been observed in Finland as well. The 
standardised mortality ratio at 20 years’ duration of diabetes in patients with 
diabetes onset between 0-14 years decreased from 3.5 in patients diagnosed 
in 1970-1974 to 1.9 in those diagnosed in 1985-1989. (45). Patients with type 
2 diabetes also have an increased risk of death, with up to four times higher 
mortality as compared to non-diabetic people (48). A 50-year-old patient 
with type 2 diabetes dies, on average, 6 years earlier than a counterpart 
without diabetes (49). The complications of diabetes continue to place a great 
burden on the health care system. People with diagnosed diabetes, on 
average, have medical expenditures that are approximately 2.3 times higher 
than what the expenditures would be without diabetes (50). Diabetes 
affects all organs, including skeletal muscle, liver, adipose tissue, kidney, 
retina, and even the bones and skin. The impact of hyperglycaemia on the 
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tissues depends on the tissue’s responsiveness to metabolic and/or 
inflammatory insults. Complications, such as retinopathy, nephropathy, 
neuropathy, and CVD (cardiovascular disease) manifestations are organ 
changes that cause direct clinical impairments.  
5.3.1 DIABETIC NEPHROPATHY 
 
Diabetic nephropathy, also known as Kimmelstiel-Wilson syndrome, nodular 
diabetic glomerulosclerosis or intercapillary glomerulonephritis, is 
characterised by a  progressive increase in the urinary albumin excretion rate 
(51). The syndrome was discovered by the British physician Clifford Wilson 
(1906–1997) and the German-born American physician Paul Kimmelstiel 
(1900–1970), and was described for the first time in 1936 (52). Diabetic 
nephropathy is accompanied by an increase in the BP and a decline in the 
glomerular filtration rate with renal failure as the ultimate endpoint of 
nephropathy progression. Diabetic nephropathy is a common complication 
of type 1 diabetes, affecting up to 30% of patients (53). Previous studies have 
shown that diabetic renal disease is a significant risk factor for increased 
mortality in type 1 diabetes (54, 55). In the absence of diabetic nephropathy, 
the long-term survival of patients is similar to that of the general population 
(56, 57). The diabetic nephropathy is categorised into stages according to 
UAER (urinary albumin excretion rate). Normal values for UAER are <30 
mg/24h or < 20 ug/min in an overnight urine collection. This is referred to 
as normoalbuminuria. Diabetic nephropathy, or macroalbuminuria, is 
present if UAER ≥300 mg/24h, or ≥ 200 ug/min is detected. The 
intermediate range of UAER ≥30 but < 300 mg/24h, or ≥20 but <200 
ug/min, is called microalbuminuria (51). The end-stage renal disease refers 
to the failure of kidney function which requires dialysis, or renal kidney 
transplantation for the survival of the patient. 
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Figure 1 Diabetic complications 
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5.3.2 DIABETIC NEUROPATHY 
 
Diabetic neuropathy is defined by the ADA (American Diabetes Association) 
as “the presence of symptoms and/or signs of peripheral nerve dysfunction in 
people with diabetes after the exclusion of other causes” (58).   
Diabetic neuropathy may affect all peripheral nerves including pain 
fibers, motor neurons, and the autonomic nervous system. The most 
common among the neuropathies are chronic sensorimotor distal symmetric 
polyneuropathy, and the autonomic neuropathies, and, thus, diabetic 
neuropathy can affect all organs and systems, as all are innervated. Diabetic 
vascular and neural diseases are closely intertwined. The neuropathies are 
thought to result from diabetic microvascular injury involving small blood 
vessels that supply nerves (vasa nervorum) in addition to macrovascular 
conditions that can result in diabetic neuropathy.  
Similar to other microvascular complications, the prevalence of diabetic 
neuropathy increases with duration of diabetes and poor glycaemic control 
(59). Severe diabetic polyneuropathy can develop in young adults even within 
a few months after the onset of type 1 diabetes if the diabetes is poorly 
controlled (60). Chronic sensorimotor distal symmetric polyneuropathy is, 
however, the most common form of neuropathy in diabetes, as more than 
80% of patients with clinical diabetic neuropathy have this form of diabetic 
neuropathy (61). Typically, patients experience burning, tingling, and 
“electrical” pain, but sometimes they may experience simple numbness. Up 
to 50% may be asymptomatic, and these patients are at risk of having 
insensate injury to their feet (58). In clinical testing, the patients have a 
sensory loss to light touch, vibration, temperature, and they may have a loss 
of the ankle reflex. Combining more than one test increases the sensitivity to 
detect diabetic distal symmetric polyneuropathy to > 87% (58). Diabetic 
autonomic neuropathy is the second most common form of diabetic 
neuropathy (58).  It causes significant morbidity and even mortality. 
Neurological dysfunction may occur in most organ systems and can be 
manifested by gastroparesis, constipation, diarrhoea, anhidrosis, bladder 
dysfunction, erectile dysfunction, exercise intolerance, resting tachycardia, 
silent ischemia, and even sudden cardiac death (62)(Fig. 1). 
Cardiovascular autonomic neuropathy is the most studied and clinically 
most important form of diabetic autonomic neuropathy. It may be indicated 
by resting tachycardia (100 beats per minute), orthostasis (a fall in systolic 
BP > 20 mmHg upon standing), or other disturbances in autonomic nervous 
system functions involving the skin, pupils, or gastrointestinal and 
genitourinary systems (58). Cardiovascular autonomic dysfunction is 
associated with an increased risk of silent myocardial ischemia and mortality 
(63) (Fig. 1). Pure sensory neuropathy is relatively rare and associated with 
periods of poor glycaemic control or considerable fluctuation in diabetes 
control. It is characterized by isolated sensory findings without signs of 
motor neuropathy. The symptoms are typically most prominent at night (62). 
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Mononeuropathies typically have a more sudden onset and involve 
virtually any nerve, but most commonly the median, ulnar, and radial nerves 
are affected. Cranial neuropathies also occur, such as paresis of the abducens 
and trochlearis nerves which cause diplopia and are commonly seen by 
ophthalmologists. The patient’s visual fields may be disturbed by nonarteritic 
anterior ischemic optic neuropathy, for which diabetes is also a risk factor 
(64). Diabetic amyotrophy may be a manifestation of diabetic 
mononeuropathy and is characterized by severe pain and muscle weakness 
and atrophy, usually in the large thigh muscles (62). 
5.3.3 MACROVASCULAR COMPLICATIONS 
 
Common macrovascular diseases are coronary heart disease, cerebrovascular 
disease, and peripheral vascular disease. The impact of these diabetic 
macrovascular complications is so great that they account for nearly 60% of 
the health care expenditures in people with diabetes (50).  
The central pathological mechanism in macrovascular disease is the 
process of arteriosclerosis which leads to the loss of elasticity and narrowing 
of arterial walls in critical organs throughout the body. Diabetes is an 
important cause of arteriosclerosis in addition to hypertension and aging.  
Atherosclerosis is a specific type of arteriosclerosis that results from chronic 
inflammation and injury to the arterial wall. In response to endothelial injury 
and inflammation, oxidized lipids from LDL particles accumulate in the 
endothelial wall of arteries, namely intima media. Monocytes infiltrating the 
arterial wall differentiate into macrophages, which accumulate oxidized 
lipids to form foam cells. The foam cells stimulate macrophage proliferation 
and attraction of T-lymphocytes which, in turn, induce smooth muscle 
proliferation in the arterial walls and collagen accumulation. The end-result 
is the formation of a lipid-rich atherosclerotic lesion, atheroma, with a 
fibrous scar. The narrowing of the arterial wall by atheromas or the rupture 
of the atherosclerotic plaque results in vascular infarction (65). The risk of 
infarction by the arteriosclerotic process may be perpetuated by the 
enhanced thrombotic potential characteristic of diabetes. Diabetes increases 
the platelet activation and decreases the endogenous inhibitors of platelet 
activity. In addition to potentiating intrinsic platelet function, diabetes 
augments blood coagulability, making it more likely that atherosclerotic 
plaque rupture or erosion will result in thrombotic occlusion of the artery 
(66). As a consequence of this precipitated arteriosclerosis, diabetes patients 
are 15 times more likely to have a lower-extremity amputation due to 
peripheral artery disease as compared to people without diabetes (67). The 
peripheral artery disease is characterized by the occlusion of the lower-
extremity arteries which causes intermittent claudication and pain and which 
may lead to lower limb amputations (68).   
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Diabetes increases the risk of CVD (cardiovascular disease) (69). 
Although the precise mechanisms through which diabetes increases the 
likelihood of arteriosclerosis and atherosclerotic plaque formation are not 
completely understood, the association between these and diabetes is clear. 
CVD is the primary cause of death in people with type 1 diabetes (70). 
 Among macrovascular diabetes complications, coronary heart disease has 
been associated with diabetes in numerous studies beginning with the 
Framingham study (71). More recent studies have shown that the risk of 
myocardial infarction in people with type 2 diabetes is equivalent to the risk 
in non-diabetic patients with a history of previous myocardial infarction (72). 
Although the risk of CVD is not as great in type 1 diabetes as in type 2 
diabetes, most likely due to the younger age of the type 1 diabetes patients, 
the CVD risk is still dramatically increased also in type 1 diabetes (69, 70, 
73). The studies have shown that these patients have a higher mortality from 
ischemic heart disease at all ages compared to the general population. In 
individuals > 40 years of age, women with diabetes experience a higher 
mortality from ischemic heart disease than men, which is in contrast to the 
non-diabetic population (70). These discoveries have led to new 
recommendations by the ADA and American Heart Association that diabetes 
be considered a coronary artery disease risk equivalent rather than a risk 
factor for future CVD events (73).   
Diabetes is also a strong independent predictor of the risk of 
cerebrovascular disease and a stroke (74). Diabetes increases the risk of 
atherosclerotic carotid artery occlusive disease which causes a 
thromboembolic threat to the central retinal artery and increases the risk of a 
stroke (75). Observational studies have shown that the cerebrovascular 
mortality rate is elevated at all ages in patients with type 1 diabetes (76). 
Diabetes particularly affects the risk of a stroke among younger patients. In a 
population with an age younger than 55 years, diabetes increased the risk of a 
stroke more than 10-fold (77). In addition to increased risk of a stroke itself, 
the sequalea of a stroke may also be worse in diabetes patients. The risk of a 
stroke-related dementia is increased threefold, and the risk of a stroke 
recurrence is increased twofold as compared to non-diabetic patients. 
Diabetes increases stroke-related mortality as well (66). 
Fortunately, the prevention of macrovascular complications by improving 
the glycaemic control and lowering the blood pressure has been as successful 
in reducing the macrovascular complications as it has been in reducing the 
microvascular complications. Studies in type 1 diabetes have shown that an 
intensive diabetes control is associated with a lower resting heart rate, and 
that patients with higher degrees of hyperglycaemia tend to have a higher 
heart rate which is associated with higher risk of CVD (78).  Even more 
convincingly, the DCCT demonstrated that during 17 years of prospective 
analysis, intensive treatment of type 1 diabetes, including lower HbA1c, was 
associated with a 42% risk reduction in all cardiovascular events and a 57% 
reduction in the risk of nonfatal myocardial infarction, a stroke, or death 
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because of CVD (55). The risk of cardiovascular events can be further 
reduced by the optimal treatment of dyslipidaemia (79, 80). 
5.3.4 THE HISTORY OF DIABETIC RETINOPATHY RESEARCH 
 
The first reports on DRP were published in the mid-19th century. Diabetic 
macular changes in the form of lipid exudates and edema were observed for 
the first time by Eduard Jäger in 1855. He published a manuscript “Beiträge 
zur Pathologie des Auges” where he included 21 fundus paintings of macular 
changes (2). Albrecht von Graefe (1828-1870) was sceptical of his findings 
and claimed that there was no proof of a cause-effect relationship between 
diabetes and retinal changes (81). The opinion of von Graefe was adopted by 
many ophthalmologists, and it was not until 1872 when Edward Nettleship 
published “Oedema or cystic disease of the retina” which provided the first 
histological descriptions of “cystoid degeneration of the macula” in patients 
with diabetes (82). In 1876, Wilhelm Manz described the typical 
neovascularisations in PDR (proliferative diabetic retinopathy),  TRD 
(tractional retinal detachment), and VH (vitreous haemorrhage) (83). In 
1890, Julius Hirschberg (1843-1925) classified DRP into four types (retinitis 
centralis punctuate, haemorrhagic form, retinal infarction, and haemorrhagic 
glaucoma), thus describing the natural course of DRP  and also creating the 
first clinical classification of  DRP (84).  Retinopathy caused by hypertension 
had been described by Markus Gunn at the end of the 19th century (85). Like 
diabetic retinopathy, it could cause visual impairment due to macular edema 
and neovascularisation. A four-grade-classification scale for hypertensive 
retinopathy was developed by Norman Keith, Henry Wagener, and Nelson 
Barker in 1939 which predicted the survival of hypertensive patients (86). 
The work of Arthur James Ballantyne in 1943 gave proof that DRP  is indeed 
a unique form of vascular retinal disorder, which is distinct from 
hypertensive retinopathy, although they share many features (87). The 
knowledge of DRP has since greatly increased, and the definition and  
classification of DRP has evolved through many stages.  
5.3.5 THE DEVELOPMENT OF RETINOPATHY SEVERITY GRADING 
 
For a long time, the classification by Julius Hirschberg was the only one 
available, and there was an obvious need for a more detailed classification 
(84). The so called Airlie House classification for DRP was developed at a 
symposium organized by the US Public Health Service in 1968 held in Airlie 
House, Warrington, PA, hence the name (88). The principle of grading 
various retinal changes in the Airlie House classification was adopted from a 
study by a Finnish group describing DRP changes following hypophysectomy 
(89-91). The Airlie House classification used five standard photographic 
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fields and stereo photographs to assess the severity of the retinopathy. The 
DRS (Diabetic Retinopathy Study), the first randomised controlled trial in 
medicine,  added two more photographic fields, inferonasal and superonasal, 
to the original Airlie House classification resulting in seven standard 
photographic fields (92). The original Airlie House grading classified fundus 
lesions into one of three categories: absent, mild to moderate, or severe (88).  
With only three levels of severity, this system was impractical for research 
purposes. The DRS, therefore, defined more severity grades with the aid of 
standard fundus photographs. The additional severity grades included severe 
background retinopathy, also known as preproliferative DRP, and PDR with 
high-risk characteristics for severe visual loss which was used as an 
indication for photocoagulation without delay in the DRS (93).  
The most detailed classification was created in the ETDRS (Early 
Treatment of Diabetic Retinopathy Study) in 1980’s. The ETDRS grading was 
based on the DRS modified Airlie House classification. The ETDRS was a 
prospective randomised controlled trial which was conducted to assess the 
use of aspirin and photocoagulation in the treatment of non-proliferative 
DRP and early PDR which did not fulfil the high-risk characteristics for 
severe visual loss as already defined in the DRS. It, therefore, needed to have 
a more sensitive scale for the early DRP changes. More steps and more 
fundus photographic risk factors were added to the scale at the mild and 
moderate end of the DRS modified Airlie House severity scale. The 12-step 
ETDRS final retinopathy severity scale was based on assessing the 
retinopathy features in seven standard 30o photographic fields (94). The 
ETDRS-scale was later modified for use with fundus quadrants instead of 
seven standard photographic fields (95). The diabetes patients may have 
findings typically associated with DRP, such as venous irregularities, retinal 
microinfarcts, or macular edema, but only when microaneurysms are 
present, the retinal changes are considered to be DRP in the ETDRS scale. In 
addition to a more detailed DRP severity scale, a logarithmic visual acuity 
test was developed. The ETDRS visual acuity test incorporated specific 
design criteria to make it more accurate than the Snellen acuity test. Both the 
ETDRS retinopathy severity scale and the ETDRS visual acuity test have now 
become standards for defining the severity of DRP and measuring visual 
acuity in research and even in clinical settings.  
5.3.6 PATHOGENESIS OF DIABETIC RETINOPATHY 
 
The mechanism by which hyperglycaemia exerts its detrimental effects in the 
retina are many. All retinal cells, such as neural retina, glial cells, vascular 
walls and blood itself, are affected by the hyperglycaemic environment. This 
causes a multitude of functional and structural changes from very early on 
(96, 97). Some of the early changes may be reversible (98).  
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Figure 2 Important biochemical pathways in the pathogenesis of diabetic retinopathy. 
Hyperglycaemia induced superoxide production (O2
_
) inhibits glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) which in turn leads to the accumulation of 
upstream glucose metabolites. These are then diverted into four different metabolic 
pathways, each of which causes vascular and interstitial tissue damage.  
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Oxidative stress has been suggested as one of the most important 
pathophysiological factors that may explain the majority of the retinal 
changes. There are four biochemical pathways with considerable cross-over 
reactions that are alternatively activated as a consequence of hyperglycaemia 
and oxidative stress (Fig. 2) (99). These pathways are thought to explain 
many of the changes leading to DRP. Hyperglycaemia induced production of 
ROS which includes O2-, H202, -OH-, and singlet oxygen, decreases GAPDH 
activity which, in turn, increases the metabolites in the upstream glycolytic 
pathway. The metabolites are then diverted into four alternative pathways, 
each of which leads to vascular and interstitial tissue damage. The four 
metabolic pathways involved are: polyol pathway, AGE (advanced glycation 
end products), activation of PKC (polyol kinase C) and hexosamine pathway 
(100).  
In the polyol pathway the affinity of aldose reductase to glucose is 
increased in hyperglycaemia. It has previously been thought that glucose is, 
therefore, converted into sorbitol and then to fructose. It would appear, 
however, that glycolytic metabolites of glucose such as glyceraldehyde 3-
phosphate, for which aldose reductase has a much higher affinity, may be the 
physiologically relevant substrate, since the glucose concentrations within 
cells are probably too low in diabetes. Several mechanisms have been 
proposed to explain how the increase in polyol pathway flux could damage 
the tissues involved. The most probable is an increase in redox stress (101).  
The activation of the hexosamine pathway causes alterations in gene 
expression which are known to lead to vascular endothelial cell dysfunction 
and other retinal changes that are commonly seen in diabetic retinopathy. 
The mechanism by which the increased hexosamine pathway flux causes 
these changes is not certain (101). The hexosamine pathway also produces 
glucosamine 6-P which leads to the increased synthesis of glycolipids, 
glycoproteins, proteoglycans and, TGF-β.  
The AGEs interact with cells by three main routes. First, the AGE-
modified serum proteins interact with vascular endothelium via AGE-
receptors causing increased cytokine and adhesion molecule production. The 
serum-derived AGEs may reach vascular pericytes via transendothelial 
trafficking or as a result of blood–retinal barrier breakdown. The serum 
AGEs may also interact directly with cell surface glycoproteins with 
damaging effects on membrane integrity and function. Second, the AGEs can 
form directly within cells from reaction of glucose or methylglyoxal with 
amino groups. Third, the AGEs cause collagen crosslinking and impair 
matrix-cell interaction with a potentially significant detrimental effect on the 
cell function (97, 102).   
In the PKC activation pathway, the intracellular diacylglycerol is 
increased in hyperglycaemia, and this activates PKC which contributes to 
increased matrix protein accumulation and also induces the expression of 
VEGF. Furthermore, hyperglycaemia activates many PKC isoforms which 
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mediate retinal blood flow abnormalities by depressing the NO production 
(101).  
There are also other mechanisms which are likely to have a role in the 
development of DRP. Low intracellular oxygen tension elevates the 
intracellular concentration of ROS which consequently limits the cell’s ability 
to hydroxylate HIF-1α, which is the key mediator of hypoxic responses. This 
leads to hypoxia induced cascade of protein synthesis which includes 
inflammatory cytokines, such as VEGF. Other intracellular molecules also 
affect the stability of HIF-1α. These include growth factors such as IGF-1 and 
IGF-2. Insulin induces the expression of VEGF and together with the 
stabilized HIF-1α may explain the initial worsening of DRP which is observed 
in improved glycaemic control (103, 104).  
Inflammatory changes have also been suggested to contribute to the 
development of DRP, since many of the observed abnormalities are 
consistent with inflammation (105). As a consequence of the many disturbed 
biochemical pathways, there are  functional changes in the retina which 
include increased blood flow causing shear stress, leukostasis, blood retina 
barrier breakdown, impaired vascular autoregulation, and decreased visual 
function (105). 
5.3.6.1 Clinical signs of diabetic retinopathy 
 
The first clinically visible lesions of DRP are vascular abnormalities. 
However, diabetes affects the entire retinal parenchyma causing structural 
and functional changes from very early on (96). There is evidence that 
suggests that the late stages of the retinopathy develop as a consequence of 
these earlier retinal changes (106). The patients with diabetes have reduced 
electrical responses as shown by electroretinography, lowered blue-yellow 
colour sensitivity, and a diminished contrast sensitivity even before the 
appearance of any microvascular lesions (96). Patients with an early 
ophthalmoscopically detectable DRP have retinal microaneurysms which 
appear as red dots on dilated funduscopic examination. The microaneurysms 
are localized dilatations of the capillaries which have been postulated to 
develop as a result of localized weaknesses in the vessel wall (pericytes), 
pressure disturbances, glial retraction/death, or endothelial cell proliferation 
in response to local capillary closure (Fig. 3)(107). Other retinopathy changes 
typical for the NPDR stages of the DRP (haemorrhages, retinal edema, lipid 
exudates, microinfarcts, IRMA) do not necessarily cause symptoms if outside 
the macular area (Fig 4). The increase in their presence and severity tends to 
predict progression towards the more advanced stages of the disease (95).   
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Figure 3 Venous irregularity (beading), microaneurysms, and mild IRMA (intraretinal 
microvascular abnormality) in the upper temporal quadrant (arrow). 
 
Figure 4 Macular edema with lipid exudates (upper arrow), intraretinal haemorrhages (lower 
arrow), and microaneurysms. 
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The hallmark of DRP  is the damage to the vascular endothelial cells and 
pericytes secondary to abnormalities in these cells themselves or in the 
nearby retinal cells. Retinal edema occurs mainly as a result of the disruption 
of the blood-retinal barrier (BRB) which leads to increased accumulation of 
fluid within or under the neuroretinal layers (108). The vascular endothelium 
is an important component of the inner BRB, and endothelial cell 
dysfunction and death are important in the development of retinopathy. The 
occlusion of the vascular lumen by white blood cells or platelets may also 
lead to the obliteration of the small capillaries (107). As the area of retina 
with acellular capillaries increases and coalesces, the terminal arterioles that 
supply these areas also become occluded (Fig. 5). Adjacent to the 
nonperfused retina, tortuous hypercellular vessels may develop, and these 
vessels are called intraretinal microvascular abnormalities (IRMA) (Fig.3). 
IRMA changes could represent both intraretinal neovascularisations, and 
dilated capillaries and this uncertainty is indicated in the term IRMA (109).  
 
 
Figure 5 Fluorescein angiogram of extensive capillary closure (arrow), enlarged foveal 
avascular zone, and macular edema. 
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As the retinal ischaemia becomes extensive other, changes can also be 
seen, such as dilated, irregular segments in retinal veins that are called 
venous beading (VB) (Fig. 3 and 5) and ischaemic intraretinal haemorrhages.  
A commonly seen change in the retinal arteries is the loss of elasticity and 
increase in the thickness of the vascular wall by the replacement of the 
vascular wall smooth muscle fibers with fibrous tissue. The changes in the 
retinal vessels may lead to branch retinal vein occlusion and even to the 
occlusion of the retinal arteries (Fig. 6). Eventually, neovascularisation 
ensues to compensate for the widespread impaired circulation and ischemia 
in the retina due to the damaged and occluded vessels (109). The definition 
of PDR (proliferative diabetic retinopathy) requires the presence of newly 
formed blood vessels or fibrous tissue resulting from the regression of new 
vessels, or both arising from the retina or optic disc and extending along the 
inner surface of the retina or optic disc or into the vitreous cavity (110).  
When neovascularisation occurs on the surface of the retina, but not at the 
optic disc, it is called NVE (neovascularisation elsewhere) (Fig. 6). When it 
occurs on the optic disc, it is termed NVD (neovascularisation at the disc) 
(Fig. 7). Severe NPDR is usually predictive of neovascularisation. However, 
sometimes the fundus may appear quiet or featureless since haemorrhages, 
microinfarctions, and IRMAs tend to disappear after an extensive capillary 
closure. The characteristic features of severe NPDR are, thus, not always 
present when neovascularisations are first recognised (110). Furthermore 
VBs and IRMAs may not always be easily distinguished from other than red-
free images, which enhance the detection of haemoglobin containing 
structures (111-114) 
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Figure 6 Venous irregularity (beading) and an early stage of neovascularisation (arrow). 
As the extent of the midperipheral capillary closure increases, so does the 
severity of the neovascularisation process, which increases in the following 
order: from one or more local NVEs to NVD and, finally, the anterior 
chamber angle with neovascular glaucoma (NVG) (115). Neovascularisations 
may become fibrotic and rarely regress even without any treatments. 
However, the proliferative process, especially if posterior vitreous 
detachment has not taken place, leads to retinal traction (Fig. 8), repeated 
haemorrhages, and, finally, TRD (tractional retinal detachment).  
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Figure 7 Neovascularisation at the disc (NVD) as an extensive fibrovascular membrane 
(upper arrow). Occluded artery (lower arrow) in the inferior nasal quadrant and 
scatter laser scars. 
Without proper treatment of PDR, the patient is at a high risk of 
becoming blind (116, 117). If vitreous detachment has taken place, the 
proliferative process is confined to the surface of the retina or the optic disc 
without the risk of TRD (110). NVEs and the remaining damaged capillaries 
have increased permeability which may lead to the accumulation of fluid in 
the macula and decreased visual acuity (118, 119). If vitreous detachment has 
occurred, it may promote the spontaneous resolution of DME (diabetic 
macular edema) and, consequently, improve visual acuity (120).  
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Figure 8 Fibrovascular traction extending from the optic disc to the upper nasal area and 
along the upper temporal archide (arrow). A smaller traction is present temporal to 
the macular area. 
5.3.6.2 Epidemiology of diabetic retinopathy 
 
Mild retinopathy changes without diabetes, indistinguishable from DRP,  are 
quite common (5-10)% in generally healthy adults that are ≥ 43 years old 
(121-124). The retinopathy without diabetes is usually associated with aging, 
hypertension, and impaired glucose metabolism, although it can occur even 
without these risk factors (121-124). The five and ten year incidences of 
retinopathy in people without diabetes have been reported to vary from 6 to 
19% in the Beaver Dam and Blue mountains eye studies (125-127). 
Hyperglycaemia significantly increases the prevalence of any retinopathy 
changes (121, 124, 128).  When retinopathy occurs in the presence of diabetes 
it is considered DRP. However, similar retinopathy changes may be found in 
many systemic diseases such as inflammation (vasculitis), blood dyscrasias, 
and any retinal vascular dysfunction, the most common being retinal vein 
occlusion and age-related macular degeneration.  
There are many studies published on the natural history and risk factors 
of DRP (129). However, many of the studies give inconsistent results 
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regarding the prevalence and incidence of different DRP phenotypes. This is 
probably related to variable study methods used (129). The most consistent 
epidemiologic evidence comes from population-based studies. One such 
study is the WESDR which began in 1979 and included 2990 type 1 and type 
2 patients across 11 counties in southern Wisconsin, USA. The patients in 
WESDR were more likely to have evidence of nonproliferative or PDR the 
longer the duration of their diabetes (130). After 20 years of diabetes almost 
all patients with onset before the age of 30 years showed some signs of 
retinopathy (131). The WESDR also showed that insulin treatment  was 
associated with an increased frequency of nonproliferative retinopathy and 
PDR in type 2 diabetes patients (130). Essentially the same results were 
shown a few years later in two separate studies from Sweden (132, 133). The 
incidence of PDR rises almost linearly after 10 years of diabetes duration 
(132, 134), and the prevalence of PDR varies between 13 and 50 % after 15-25 
years of diabetes in patients that use insulin (131, 135).  The risk of 
developing high-risk characteristics PDR in the ETDRS after a 1-year follow-
up ranged from 1% (95%CI 0.6-1.1) for the patients with mild DRP at 
baseline, to 3 % (95%CI 2-5%) – 9 % (95%CI 7-11) for moderate, 15 % (95%CI 
12-17) for severe, and 45 % (95%CI 34-55) for very severe NPDR. The 
incidence of high risk characteristics PDR rose to 16 % (95%CI 13-18 ), 27 % 
(95%CI 24-30) – 39 % (95%CI 36-43 ), 56 % (95%CI 52-60), and 71 % 
(95%CI 62-80)  after 5 years, respectively (136). 
In the WESDR, the patients whose age at the diagnosis of diabetes was 
less than 30 years and who were taking insulin, the prevalence rates of DME 
(diabetic macular edema) varied from 0% in those who had had diabetes for 
less than 5 years to 29% in those whose duration of diabetes was 20 years or 
more. For those whose age at the diagnosis was 30 years or older, the 
prevalence rates of DME varied from 3% in those who had diabetes less than 
5 years to 28% in those whose duration of diabetes was 20 or more (137). 
Similar prevalences have been reported also in other studies in which the 
prevalences of DME ranges between 12 to 29 % after 18-25 years of diabetes. 
DME has usually been found to be more common with the diabetes onset 
after 30 years of age and with insulin use (130, 132, 138). The natural course 
of DME is significantly different from PDR, since DME may resolve by its 
own, without any treatments and also without producing severe visual 
disturbances (139). This is not the case with PDR which is almost certain to 
produce severe visual disturbances that are eventually noticed by the patient 
(116, 117). DME also differs from PDR in that it  causes a more severe visual 
loss in the elderly patients which may be related to the longer natural 
duration of edema in these patients (108). The natural course of DME may 
also be reflected upon the incidence rates of DME. The incidence of DME is 
likely to be higher in studies in which annual examinations are performed as 
compared to studies with less frequent examinations. This is because 
resolved DME may not be accounted for in studies with less frequent 
examinations. For example the annual incidence of DME in type 1 diabetes 
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patients examined yearly with diabetes duration from 10 to 20  years is 6.7% 
which is approximately three times the rate calculated from WESDR data 
from a similar era (140). A third feature of DME that makes it different from 
PDR is the requirement of stereoscopic fundus examination for the 
classification of treatable lesions (141). The requirement for stereoscopic 
fundus examination may also result in a larger variation in the prevalence 
estimates. 
There have been differences in the prevalences of DRP between various 
ethnic groups (142, 143). In the third National Health and Nutrition 
Examination Survey in the USA, the prevalence of DRP was 46% higher in 
blacks and 84% higher in Mexican Americans than in whites with type 2 
diabetes (143). Studies in South Africa and the UK report a similar 
prevalence of DRP between people of African, European, and Indian origin 
with type 2 diabetes (144), between Asians and Europeans (145), and 
between black West-Indians, Jamaicans, and Caucasians (146) The 
differences between the ethnic groups are probably related to differences in 
predisposing  conventional risk factors because when adjusted for baseline 
variables, ethnicity has not been associated with the prevalence of sight-
threatening retinopathy (142, 144-146).  
The effect of sex has shown inconsistent associations with DRP. In the 25-
year analysis of the WESDR, male sex was associated with retinopathy 
progression, and males also had less improvement in DRP than females. 
However, PDR was not associated with the male sex in the WESDR (131). The 
effect of sex may be modified by the age at onset of type 1 diabetes. The 
higher the age at onset, the higher the risk of microvascular complications in 
males as compared to females (147).  
The medical and ophthalmic care of diabetes patients has improved over 
time. It has been shown in many studies that the DRP incidence and 
associated severe visual loss has been greatly reduced (148, 149). In a study 
of elderly Medicare beneficiaries diagnosed with diabetes, those diagnosed 
with diabetes in 1999 and in 2003 showed lower rates of NPDR and PDR 
within 1 year after diagnosis and during 6 years of follow-up as compared to a 
cohort diagnosed in 1994. Similarly, six-year rates of surgical procedures for 
DRP were lower among beneficiaries in the 1999 cohort than in the 1994 
cohort (150). In a meta-analysis of temporal trends of DRP progression, the 
overall incidence of PDR and severe visual loss in studies after 1985 (e.g., 
2.6% for PDR and 3.2% for severe visual loss at 4 years) were substantially 
lower than the rates observed before 1985 (19.5% for PDR and 9.7% for 
severe visual loss at 4 years). The substantially lower progression rates may 
reflect improvements in the overall care and the management of diabetes and 
associated risk factors (151), together with earlier identification of type 2 
diabetes (149). A decline in severe DRP in type 1 diabetes has also been 
observed in the FinnDiane study population from the 70’s to the end of the 
century (152). The incidence of severe visual loss due to DRP has been 
reduced by half during the same time in Finland (153). 
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5.3.6.3 Risk factors for diabetic retinopathy 
 
The risk factors for DRP can be categorized roughly into those that can and 
those that cannot be treated (Table 1). Although epidemiological studies are 
able to show associations between different retinopathy phenotypes and 
potential risk factors, these associations may be obscured by various known 
and unknown confounding factors. For example dyslipidaemia may be 
associated with hyperglycaemia and, thus, produce erroneous results in the 
statistical analysis. Although known confounding factors can be taken into 
account in multivariate models, randomised controlled trials are ultimately 
needed to establish a causal relationship between a risk factor and the 
outcome of interest. In DRP, such studies are available regarding glycaemic 
control, BP and, triglycerides.   
DRP seems to have an inherent momentum of progression once severe 
enough. The more severe the NPDR, the more likely it is to progress even 
further (94, 95, 154-157). To prevent the progression of retinopathy, the most 
important treatable risk factor is considered to be the glycaemic control. The 
threshold for the HbA1c  in making the diagnosis of diabetes was chosen to be 
6.5 % in part because of the sharp increase in the prevalence of retinopathy 
in patients whose HbA1c rises above this level (17). It has also been noted in 
many randomised controlled trials, that a poor glycaemic control increases 
the incidence and the progression of DRP in both type 1 and type 2 diabetes 
(158-160). In the DCCT primary prevention cohort, the risk of any DRP was 
reduced by 27% over a mean follow-up of 6.5 years in the conventional vs. 
intensive blood glucose control groups (90 vs. 70%)(161).  For the primary 
prevention cohort, the cumulative 8.5 years rates of 3-step or more DRP 
progression were 54.1% and 11.5% in intensive vs. conventional groups 
respectively. For the secondary prevention cohort, the cumulative 3-step 
progression was 49.2% and 17.1%, respectively (157). In the ADVANCE trial 
with type 2 diabetes patients, the intensive glycaemic control did not 
decrease the DRP progression, although it decreased the progression of 
nephropathy (162). 
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Table 1. Risk factors for retinopathy progression. Level of evidence from  selected key 
studies. 
*The study included patients with type 1 diabetes 
 
 
 
Treatable risk factors Effect Type of study Studies 
Poor glycaemic control Increases risk Randomised controlled DCCT*,  UKPDS 
High blood pressure Increases risk Randomised controlled UKPDS 
High triglycerides Increases risk Randomised controlled FIELD, ACCORD 
High cholesterol Effect not certain Prospective observational ETDRS* 
Diabetic nephropathy Increases risk Population-based prospective WESDR* 
Anaemia Effect not certain Prospective observational ETDRS* 
Large waist-to-hip ratio Increases risk Prospective observational EURODIAB* 
Pregnancy Increases risk Prospective observational 
DIEP*, DCCT*, 
EURODIAB* 
Cataract surgery Effect not certain Observational Several cohort studies* 
Smoking Effect not certain Prospective observational WESDR*, EURODIAB* 
Risk factors not treatable Effect Type of study Studies 
Diabetes duration Increases risk Population-based prospective WESDR* 
Age at onset of diabetes Modifies risk Observational Several cohort studies 
Familial susceptibility Increases risk Prospective observational DCCT* 
Candidate genes Effect not certain Observational Several cohort studies* 
Myopia Effect not certain Population-based prospective WESDR* 
High intraocular pressure Effect not certain Population-based prospective WESDR* 
Large venular diameter Increases risk Population-based prospective WESDR* 
Smaller retinal 
arteriole/venule ratio, A/V 
nicking,, focal arteriolar 
narrowing 
Increases risk Cross-sectional ARIC 
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Evidence for a beneficial effect of lowering of the BP in type 2 diabetes 
patients comes from the UKPDS study (163) where a 2-step or more 
deterioration on the ETDRS scale was significantly different at 4.5 years of 
follow-up with 25% less patients in the tight BP control group progressing 2 
steps or more as compared to the less-tight BP control group. Patients 
allocated to tight BP control had a 35% reduced risk of laser treatment, and 
42% reduced risk of laser-treated DME (163). However, the positive effect of 
BP lowering was not statistically significant in the subsequent ACCORD and 
ADVANCE–trials (160, 164). The lowering of triglycerides with fenofibrates 
in type 2 diabetes patients has been shown to reduce the progression of DRP 
in two randomised controlled trials. In the ACCORD study, the odds of DRP 
progression were reduced by 40% in patients with fenofibrate along with 
statin treatment, and in the FIELD study, the risk of the  first laser treatment 
was reduced by 31% in the fenofibrate group (160, 165). However, there are 
no large-scale randomised controlled trials investigating the effects of statins 
alone on the progression of DRP, despite the fact that total cholesterol and 
HbA1c were the only factors that predicted the development and persistence 
of severe visual loss due to PDR and DME in the ETDRS (166). The 
improvement of glycaemic control is usually associated with a less rapid 
progression of DRP over extended follow-up periods. However, if the 
glycaemic control is greatly improved over a short period of time, there can 
be a paradoxical worsening of DRP. This has been shown in many studies 
(157, 167-171). The analyses of the DCCT data indicate that the magnitude of 
the change in HbA1c is more important than the rate of change. The most 
important risk factors for early worsening were higher HbA1c level at 
screening and the magnitude of the reduction of this level during the first 6 
months after randomisation. DCCT found no evidence to suggest that more 
gradual reduction of hyperglycaemia might be associated with less risk of 
early worsening (172). Despite identical mean HbA1c values, patients may 
show a large variation in their long-term glycaemic profile. Further analyses 
of the DCCT also indicated that variability in the long-term glycaemia, 
defined as intrapersonal standard deviations (SDs) of a quarterly measured  
HbA1c, is a risk factor for a 3-step progression of DRP on the ETDRS 12-step 
severity scale (173).  
Evidence for other risk factors that can be treated comes from 
observational studies. Microalbuminuria and diabetic nephropathy have 
been associated with DRP and DME especially in the younger onset patients 
(134, 174). The association between nephropathy and retinopathy has been 
inconsistent, and in some studies no association has been found (175, 176). 
The reduction of systemic fluid overload by haemodialysis may improve or 
even resolve DME (177). A similar improvement and stabilization of DRP has 
been noted after renal transplantation (178, 179).   
There are case reports suggesting that anaemia can exacerbate the 
development of PDR and DME (180, 181). Erythropoietin treatment has been 
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associated with the improvement of DME and visual acuity (182). In the 
ETDRS, low haematocrit increased the risk for severe PDR during a five year 
follow-up (95). Likewise, in a study from northern Finland, patients  with 
normocytic anaemia tended to have an increased risk of DRP, especially of 
the severe form (183). However, in population-based studies, haematocrit 
has not always been associated with the prevalence or severity of DRP (184).   
In the EURODIAB prospective complications study, WHR (waist-to-hip 
ratio) was an independent risk factor for the development of PDR in patients 
with type 1 diabetes (185). Higher WHR increased the incidence of DRP in 
type 2 diabetes patients in the prospective Hoorn study where it was a more 
important risk factor than BMI (body mass index) (186).  
Pregnancy in type 1 diabetes induces a transient increase in the risk of 
DRP. The Diabetes in Early Pregnancy Study (DIEP) showed that elevated 
HbA1c at baseline and the magnitude of improvement of glucose control 
through week 14 were associated with a higher risk of progression of DRP 
(187). Fortunately, the long-term risk of progression of DRP seems to remain 
unaffected by pregnancy. Although individual patients showed a transient 
worsening of DRP during pregnancy in DCCT, even to the proliferative levels, 
their mean levels of DRP were comparable to those in patients who had not 
become pregnant within each treatment group at the end of the DCCT  (188). 
Compared with nonpregnant women, pregnant women in the intensive 
treatment group had a 1.63-fold greater risk of any worsening of their 
retinopathy during pregnancy. The risk was 2.48-fold greater for pregnant vs. 
non-pregnant women in the conventional group. The transient nature of 
DRP worsening was also shown in EURODIAB study where having a first or 
subsequent pregnancy did not seem to be a risk factor for a long-term 
progression of any microvascular complications (189). 
It has been suspected for a long time that cataract surgery can exacerbate 
DRP, but the evidence has been inconsistent which may be due to significant 
advances in the surgical techniques. Since the advent of the modern 
phacoemulsification technique, the cataract surgery does not seem to cause 
clinically important DRP progression when the preoperative DRP is less 
advanced than PDR (190-193). There is, however, evidence that 
uncomplicated phacosurgery can be associated with the onset or worsening 
of DME (diabetic macular edema) (190, 192, 194).  
The relationship between smoking and DRP appears to be complex and 
probably mediated through some confounding factors such as worse 
glycaemic control in patients who smoke. The independent significance of 
smoking on the progression of DRP is, therefore, difficult to assess (195-197).  
The above mentioned risk factors are to a certain extent treatable, but in 
addition to these factors, there are several factors that are not treatable. The 
most important factor is the length of the hyperglycaemic exposure itself. The 
longer the diabetes duration, the higher the cumulative incidence and risk of 
DRP (130).  Interestingly, the effect of diabetes duration on the risk of DRP 
may be nonuniform. The onset of type 1 diabetes before puberty appears to 
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prolong the time to DRP with an increasing delay in the onset of 
complications in those with a longer prepubertal diabetes duration (198). 
The effect of prepubertal duration on the risk of DRP is, thus, smaller than 
the postpubertal diabetes duration (199, 200). In particular, the diabetes 
duration without DRP is significantly longer (2-4 years) for those diagnosed 
before the age of 5 years compared with those diagnosed after the age of 5 
(198). This difference in diabetes duration without DRP may be related to the 
observation that diabetes onset at puberty is associated with an increased 
risk of DRP (200-202).  In addition to modifying the survival time free of any 
DRP, the age at onset may also modify the DRP phenotype, as was shown in 
the EURODIAB study, where the onset before puberty was associated with an 
increased risk of PDR (185). The finding of the age at onset as a risk factor for 
DRP is not limited to type 1 diabetes. In type 2 diabetes the higher age at 
onset has been shown to be associated with a reduced risk of DRP (203). The 
risk difference may be related to residual insulin secretion. The DCCT data 
indicated that patients with any residual C-peptide secretion, but especially 
those with the highest stimulated concentrations, had a reduced incidence of 
DRP and nephropathy (204). The patients with any residual C-peptide 
secretion were also slightly older than the patients with no C-peptide 
secretion (204). However, the role of C-peptide has been somewhat 
controversial since it has not been linked to DRP in other studies (131).  
Genetic factors are likely to play a role in the development of DRP. 
Previous studies have been able to show familial clustering of severe NPDR 
in families with type 2 diabetes, (205, 206) and in families with a mixture of 
both type 1 and type 2 patients (207). The heritability has been reported to be 
27 % for DRP and 25 % for PDR in a mixed sample of type 1 and type 2 
diabetic siblings (208). Three genome wide linkage scans have offered 
suggestive evidence of linkage, but on a number of different chromosomes in 
patients with type 2 diabetes (209-211). The first genome wide association 
analysis was published in 2011 in type 2 diabetes and suggested an 
association to loci in chromosome 5 (212). The associations with various 
biologically relevant candidate genes have been extraordinarily difficult to 
replicate (213, 214). This is probably because the heritability estimates are 
typical of multifactorial inheritance that would require a very large sample 
size to show significant associations. 
There has been a suspicion for a long time that some ocular factors could 
be involved in the development of DRP. Myopia has been associated with less 
severe DRP in some studies, but the association has been inconsistent (215-
221). A higher intraocular pressure or bilateral glaucoma do not appear to 
affect the progression of DRP (215, 216). In the ARIC study (Atherosclerosis 
Risk in Communities study), smaller retinal arteriole/venule ratio, presence 
of retinal arteriole/venule nicking, and focal arteriolar narrowing were 
independently associated with the severity of DRP after controlling for 
systemic variables (184). Independently of the DRP severity level and the 
systemic factors, the widening of the retinal venular but not arteriolar 
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diameter was associated with subsequent incidence and progression of DRP 
(222). One ocular factor that encouraged the use of light photocoagulation in 
the treatment of DRP was the observation that the eyes with retinochoroidal 
scarring from trauma or inflammation had a markedly reduced prevalence 
and severity of diabetic DRP (223, 224). 
5.3.6.4 Treatment of diabetic retinopathy 
 
Severe visual loss is mostly due to either PDR or DME (166). The most severe 
form of DRP is PDR, and without any treatments most of the patients will 
become blind after 5-10 years (116, 117). DME does not usually lead to 
blindness, but it may cause low vision and, thus, affect the quality of life. 
Laser treatment is considered the cornerstone of the treatment of both PDR 
and DME. The beneficial effect of laser treatment in severe PDR was clearly 
shown by the DRS. The laser treatment in DRS  was specified as widespread 
scatter (panretinal) photocoagulation with 800 to 1600 500 µm laser burns 
of 0.1 seconds duration (225). Severe visual loss was defined in the DRS as 
visual acuity <5/200 in two consecutive visits at 4 months apart. DRS 
demonstrated that the risk of severe visual loss was reduced to half by 
photocoagulation treatment (225). As a continuation to the DRS, the ETDRS 
recruited 3 711 patients of whom 1 444 patients had type 1 diabetes and 2 267 
patients had type 2 diabetes (226). These patients were followed regularly for 
3-9 years with 4-month intervals. Those patients with either a poor prognosis 
for 5-year survival or only less than a mild background DRP in either eye 
were not considered eligible for the study. The ETDRS study showed that 
laser photocoagulation had a beneficial effect of reducing the so called CSME 
(clinically significant macular edema). The ETDRS demonstrated that a focal 
or scatter laser treatment of DME reduced the risk of moderate visual loss by 
half in eyes fulfilling the CSME definition, whereas the effect was less obvious 
in the group with DME without CSME characteristics (139). The moderate 
visual loss was defined in the ETDRS as loss of 15 letters or more between the 
baseline and follow-up visits, equivalent to doubling of the visual angle (136). 
There were numerous studies even before the ETDRS which demonstrated 
the beneficial effect of laser treatment on DME (227-234). However, these 
studies were difficult to compare and to apply as treatment guidelines. The 
ETDRS provided such a guideline with proven efficiency for treating CSME 
with focal or grid laser treatments. In the focal treatment, microaneurysms 
and other focal leakage sites received 50-100 µm laser burns of 0.1 s duration 
or less. The treatment of lesion closer to 500 µm to the fovea was not 
required initially. However, if the vision was less than 20/40 and the retinal 
edema and leakage persisted, treatment of lesions up to 300 µm from the 
center was recommended, unless there was a perifoveal capillary dropout 
which might have been worsened by the laser treatment. In the grid 
treatment, areas of diffuse leakage or nonperfusion within 2 disc diameters 
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of the center of the macula were treated in a grid pattern. The goal was to 
produce a light/moderate intensity burn not more than 200 µm in diameter. 
A spot size of 50-200 µm was used to achieve this. A space one burn wide 
was left between each burns and a minimum distance of 500 µm was kept to 
fovea. The ETDRS protocol did not specify the number of burns used in the 
treatment of CSME (136, 139).  Later on, the ETDRS also showed the positive 
effect of laser treatment in severe NPDR especially in type 2 diabetes patients 
(235). Today, the number of burns needed and the extent of the area treated 
varies according to the severity and location of PDR and location of severe 
NPDR as well as the technical qualities of laser equipment 
The laser treatment may have adverse side-effects, the most notable of 
which are the constriction of visual fields and a slight reduction of visual 
acuity following dense panretinal photocoagulation (225). In ETDRS, these 
adverse effects were most evident in the months immediately following the 
treatment and were less frequent in eyes assigned to less extensive scatter 
photocoagulation (136). If a patient has less than severe NPDR or does not 
have CSME, the patient may be followed and treated if progression to the 
aforementioned severity levels takes place (235). In more advanced stages of 
PDR, the patient will have VHs and/or TRDs. The beneficial effect of 
vitrectomy at this stage was reported first by Robert Machemer (236). In the 
DRVS type 1 diabetes patients had a three times higher risk of attaining good 
visual acuity (≥10/20) due to early vitrectomy as compared to conventionally 
managed patients (35.6%  vs. 11.7%) (237).  
When DRP is less severe, the treatment focuses on systemic factors such 
as BP, glycaemic control and lipids (238, 239). The treatment of DME and 
DRP is changing at the moment. Emerging new treatments, such as anti-
VEGF injections and cortisone injections and implants, are promising 
alternatives that are already widely used.  However, research into the every-
day-clinical protocols and the long-term effects of these treatment modalities 
is scarce, and further research is still needed (239-242).  
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6 THE AIMS OF THE STUDY  
A large proportion of the risk of sight-threatening, severe DRP remains 
unexplained.  There are well-established risk factors for DRP such as 
diabetes duration, the level of hyperglycaemia, and BP. However, these risk 
factors explain much less than half of the risk (12, 13).  Therefore, the aim of 
the present study was to elucidate other risk factors for the development of 
sight-threatening DRP like PDR and CSME in type 1 diabetes. 
6.1 STUDY I 
Familiality may affect the progression of DRP. Whether PDR also clusters in 
families is not known. The aim of the study was to assess the familial 
clustering of PDR in patients with a longstanding type 1 diabetes and to 
estimate the degree of familiality by calculating the h2 heritability of PDR. 
6.2 STUDY II 
Age at the onset of diabetes modifies the risk of DRP. However, it is not 
known how a late age at onset of type 1 diabetes affects the risk of PDR as 
compared to a very early onset of type 1 diabetes, whether young age at onset 
is a protective factor even in the long run, or whether it only delays the onset 
of PDR. Therefore, the aim of this study was to elucidate how the age at onset 
of type 1 diabetes influences the long-term risk of PDR in patients with type 1 
diabetes.  
 
6.3 STUDY III 
Despite identical mean HbA1c values, patients may have a large variation in 
their long-term glycaemic profile which has shown to affect the progression 
of NPDR (173). Whether HbA1c variability is also associated with a higher risk 
of laser treatment and PDR is not known. Therefore, the aim of this study 
was to investigate the effect of HbA1c variability on the long-term risk of laser 
treatment and PDR. 
6.4 STUDY IV 
Several risk factors for DME have been identified. However, the long-term 
incidence of CSME has not yet been studied with specific focus on the age at 
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onset of type 1 diabetes. Therefore, the aim of this study was to assess the 
impact of age at onset of type 1 diabetes on the long-term incidence and risk 
of CSME and to see what the differences are in risk factors between CSME 
and PDR. 
6.5 STUDY V 
In addition to a genetic component, the familial clustering of DRP is likely to 
include shared, non-genetic factors that are largely unknown. The aim of this 
study was to elucidate whether diabetes onset within sibships, as adjusted for 
conventional risk factors, age at onset of type 1 diabetes and sibship size 
influences the long-term risk of PDR. 
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7 PATIENTS AND STUDY DESIGN 
7.1 THE FINNDIANE STUDY POPULATION 
 
The FinnDiane study was initiated in 1997 primarily to find out why one 
third of type 1 diabetes patients develop nephropathy. This aim was soon 
extended to include all late complications of type 1 diabetes. A longitudinal, 
observational patient database, consisting of clinical, genetic, and 
environmental variables was collected from a large number of participating 
study centres (Table 2). The participating study centres comprise diabetes 
and renal outpatient clinics at all five university central hospitals, all 16 
central hospitals, the majority (n= 27) of all regional hospitals, and 31 major 
primary health care centres in Finland. All adult patients with type 1 diabetes 
at these centres were invited to participate and 78% responded positively 
(243). The FinnDiane database now comprises over 4 800 patients with type 
1 diabetes and the geographic distribution of the patients closely follows the 
distribution of the general population of Finland (Fig. 9). The collection of 
the prospective follow-up data started in 2004. To date, nearly 4 000 
FinnDiane-patients have either been re-examined or, alternatively, their 
medical files reviewed by the FinnDiane investigators at the participating 
study centres. As the number of type 1 diabetes patients is approximately 
30 000 in Finland, the FinnDiane study therefore represents 16% of all type 1 
diabetes patients in Finland. The study protocol is in accordance with the 
Declaration of Helsinki, and was approved by the ethics committee of the 
Helsinki University Central Hospital. The DRP study presented here was 
undertaken as one of the many substudies of the FinnDiane Study. 
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Table 2. Clinical characteristics of the FinnDiane patients (n=4 895), male/female               
2 585 / 2 310.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The values are expressed as means ± standard deviations, or medians (IQR=interquartile 
range). MAP= Mean Arterial Pressure, BMI= Body Mass Index,  CRP =C-reactive protein, 
WHR= Waist-to-Hip Ratio,  ASA=Aspirin (Acetylsalicylic Acid), AHT= Antihypertensive 
Treatment,  MSBP =Mean systolic Blood Pressure,  MDBP =Mean Diastolic Blood Pressure 
 
 
 
Duration of diabetes (years) 21.8±12.2 
Age (years) 38.8±12.4 
Age at onset (years) 17.0±11.1 
HbA1c (%) 8.4±1.5 
MSBP (mmHg) 135±18 
MSDP (mmHg) 80±10 
MAP(mmHg) 98±11 
AHT (%) 38% 
ASA treatment (%) 13% 
Diabetic Nephropathy (%) 22% 
Triglycerides (mmol/l) 1.0 (IQR 0.7-1.4) 
Total Cholesterol (mmol/l) males 5.0±1.0 
HDL Cholesterol (mmol/l) males 1.5±0.4 
HDL Cholesterol (mmol/l) females 1.7±0.5 
Statin treatment (%) 11% 
WHR males 0.91±0.07 
WHR females 0.82±0.07 
BMI 25.1±3.6 
History of smoking 23% 
Mortality until 24.3.2009 (%) 10% 
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Figure 9 Distribution of the FinnDiane-patients. Each dot represents the home address of a 
FinnDiane study patient. 
7.2 PATIENTS IN STUDIES I AND V 
 
The heritability of PDR was calculated in study I in siblings with type 1 
diabetes. As a part of the baseline visit, the patients answered a question 
whether any of their close relatives had type 1 diabetes, as defined by having 
an age at onset of 40 years or less and insulin treatment initiated within one 
year of the diagnosis. These criteria identified 188 families with at least two 
siblings with type 1 diabetes. All siblings were contacted and those siblings, 
who agreed to take part, signed a consent form and were studied at a 
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FinnDiane center. The same patient data was used in study V which assessed 
the impact of diabetes onset within siblings on the long-term risk of PDR.  
Records of fundus examinations by dilated ophthalmoscopy and/or 
fundus photographs were obtained for 369/396 (93%) of the patients. Both 
were available for 217/369 (59%) patients. The fundus photographs taken for 
screening or documentary purposes were available for 251/369 of the 
patients (68%). These patients had been photographed on a median of 3 
(IQR 1-5) times. A diabetologist’s evaluation of the fundi was the only source 
of information for 3/369 of the patients, all of whom had a mild diabetic 
retinopathy. All the other patients had had dilated ophthalmoscopies carried 
out by an ophthalmologist. 
7.3 PATIENTS IN STUDY II 
 
In the study of the effects of age at onset of type 1 diabetes on the long-term 
risk of PDR, a sample of 1 117 was drawn from the FinnDiane database. The 
inclusion of the patients into this study was based on the ascending order of 
the FinnDiane patient identification number. Thus, the consecutively 
recruited patients from the very beginning of the FinnDiane study were the 
first to be included in the study. This approach has two advantages. First, 
there should be no significant biases with regards to the treatment of 
diabetes and its complications. Secondly, these patients had the longest 
duration of type 1 diabetes as they were the first ones to participate in the 
FinnDiane study.  
Only in 19/367 (5.2%) patients, PDR was discovered at their first fundus 
examination by an ophthalmologist. Thus, there were no available reference 
points for these patients before they had developed PDR. All the other 
patients (n=348) had had at least one ophthalmic examination on a median 
of 0.7 (0.3-1.8) years prior to the diagnosis. Additionally, records of 
treatment and follow-up were available for nearly all (364/367) patients with 
PDR. 
7.4 PATIENTS IN STUDY III 
 
The effect of HbA1c variability was assessed in 2 019 FinnDiane Study 
patients. The patients were studied in two partially overlapping subcohorts 
with either verified first laser treatment (n=1459) or DRP severity and 
progression graded from ophthalmic records with the ETDRS scale (n=1 346) 
(Fig 9). There were 786 overlapping patients between the subcohorts. The 
laser treatment subcohort consisted of 1 459 patients that were followed up 
for the occurrence of the first laser treatment. In January 2012, the 
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FinnDiane database had 2 019 patients with follow-up data on whether the 
patient had been laser-treated (yes/no) as verified from medical files by the 
attending physician, data on the year of the first laser treatment, and data on 
at least two HbA1c measurements one year apart. Of the 2 019 patients, 1 459 
did not have any prior laser treatment episodes before the first FinnDiane 
visit. The patients that were not included in the subcohort of 1 459 patients 
had either been laser-treated before the first FinnDiane visit, or the 
ophthalmic data and/or serial HbA1c measurements were insufficient in 
order to construct a follow-up period after the first FinnDiane visit. 
The specific risk factors for PDR were further analysed in a subcohort of  
1 346 patients. Fundus photographs taken for screening or documentation 
purposes and/or records of dilated slit-lamp fundus examinations performed 
by a specialist in ophthalmology were obtained for 1 346 consecutively 
recruited patients. These patients were the earliest to have been recruited in 
the FinnDiane study and had, thus, the longest duration of diabetes. The 
records of fundus examinations by ophthalmologists were available for           
1 076/1 346 (79.9%) patients and fundus photographs were available for         
1 052/1 346 (78.2%) of the patients. The patients had been photographed on 
a median of 3 (IQR 1-5) times per patient. All the patients who were not 
examined by ophthalmologists had had serial fundus photographs. Both 
ophthalmic records and photographs were available for 782/1 346 (58.1%) 
patients. 
 
 
 
 
 
 
 
 
 
Figure 10 The PDR and laser treatment subcohorts (n=2 019). There were 786 overlapping 
patients between proliferative retinopathy (PDR) (n=1 346) and laser treatment      
(n =1 459) subcohorts.  
7.5 PATIENTS IN STUDY IV 
 
As for the study II, the inclusion of patients for this study was based on an 
ascending order of the FinnDiane patient identification number. However, in 
this study, the fundus photographs were required for every patient which 
made the cohort slightly different from that used in study II. The patients 
had been photographed on a median of 3 (IQR 1-5) times per patient. 
Roughly one third of the patients in study II were, therefore, not included in 
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this study. The data also included patients that were recruited later for study 
I, but this did not significantly shorten the mean duration of diabetes as 
compared to study II.  
The DRP and maculopathy status was determined in 1 354 patients. The 
indications for each individual laser treatment and for each laser-treated eye 
were verified from ophthalmic files for all the 516 patients that had received 
any laser treatment. The patients had received a median of 5 (IQR 3-7) laser 
treatments for the right eye and 5 (IQR3-8) for left the eye, with a total of 11 
(IQR 7-16) laser treatments. Those patients, whose laser treatment was 
performed with the specific intent to reduce macular edema and who had 
fundus photographs consistent with the CSME definition (i.e. hard exudates, 
microaneurysms/haemorrhages, or photocoagulation burns in macular 
area), were considered to have CSME. Laser-treatment alone was not taken 
as evidence of CSME or PDR since severe NDRP is also an indication for 
laser photocoagulation. In 29/242 (12%) patients, CSME was discovered at 
their first fundus examination by an ophthalmologist. Thus, there were no 
available reference points for these patients before they had developed 
CSME. All the other patients (N=213) had had at least one ophthalmic 
examination on a median of 1.9 ±1.8 years prior to the CSME.  
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8 METHODS 
8.1 MEDICAL HISTORY 
 
The data were collected at the regular visits to the patients’ attending 
physician. Patients filled in a questionnaire which was then verified from the 
medical files by the attending physician. The questionnaire included a 
standardised check list regarding medication, the year of the onset of 
diabetes and the year of initiation of permanent insulin treatment. The check 
list also included questions about microvascular and macrovascular events, 
such as the year of the first laser treatment, and renal and cardiovascular 
status. The data on all-cause mortality were obtained until 24.3.2009 from 
the Population Register Centre of Finland. 
8.2 ANTHROPOMETRIC MEASUREMENTS 
The patients’ weight was measured using a standardized scale and registered 
to closest 0.1 kg. Height was registered to the closest 1 cm. Waist 
circumference was measured midway between the lowest rib and the iliac 
crest and hip circumference at the widest part of the gluteal region. BP was 
measured twice in the sitting position using a mercury sphygmomanometer 
after a rest of at least 10 min, or an automated BP measurement device in 
accordance with the clinical practice at the local study centres. MAP (mean 
arterial blood pressure) was calculated according to the formula: MAP = 
diastolic BP + 1/3(systolic BP - diastolic BP). BMI was calculated as weight 
divided by height squared (kg/m2). WHR was calculated by dividing waist 
with hip circumference.  
8.3 LABORATORY MEASUREMENTS AND ASSAYS 
 
Blood was drawn for laboratory measurements. These measurements 
included HbA1c using standardized assays at the participating study centres. 
Serum lipoproteins were measured centrally at the research laboratory of the 
Helsinki University Central Hospital with automated methods that use the 
Cobas Mira analyser (Hoffman La Roche, Basel, Switzerland). An equation 
for the eGDR modified for use with HbA1C instead of HbA1 (eGDR = 24.4- 
12.97•WHR - 3.39•AHT- 0.6•HbA1C), was used as a measure of insulin 
sensitivity. In this equation WHR stands for waist to-hip ratio and AHT for 
antihypertensive treatment and/or BP ≥140/90 mmHg (yes=1, no=0) (244). 
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AHT was defined as the current use of at least one antihypertensive drug. C-
peptide was measured with radioimmunoassay (until 2004 LKB Wallac, Mt. 
Waverley VIC, Australia, and thereafter Riagamma Delfia, PerkinElmer, 
Waltham, MA, USA). CRP was measured with radioimmunoassay (Orion 
Diagnostica, Espoo, Finland) (245). The renal status was based on the UAER 
in two out of three overnight or 24-hour urine collections. The UAER was 
centrally determined by radioimmunoassay until November 2002 
(Pharmacia, Uppsala, Sweden) and, thereafter, by immunoturbidimetry with 
a correlation coefficient of 0.96 between the two methods. The patients were 
divided by renal status into four categories: Those with normal UAER (<20 
µg/min or <30 mg/24h), microalbuminuria (UAER ≥ 20 and <200 µg/min 
or ≥ 30 and < 300 mg/24h), and macroalbuminuria (UAER ≥200 µg/min or 
≥300 mg/24h). The patients were considered to have ESRD if they had 
received a kidney transplant or if they were undergoing dialysis treatment. 
Diabetic nephropathy (yes/no) was defined as persistent macroalbuminuria 
or ESRD 
8.4 RETINOPATHY DATA 
8.4.1 LASER TREATMENT 
 
In Finland, the national guidelines for the screening and treatment of DRP 
were published already in 1992 (246), and updated in 2006 (247). 
Consequently, the main indications for laser treatment such as CSME and 
PDR have been well-recognised by ophthalmogists as an important 
indication for laser treatment. Since laser treatment is regarded a surgical 
procedure, its indications are invariably stated in the ophthalmic records. 
The indications for each individual laser treatment session and for each 
laser-treated eye were verified from the ophthalmic files for all patients that 
had received any laser treatment. The patients with laser treatment had 
received a median of 5 (IQR 3-7) laser treatments for the right eye and 5 
(IQR 3-8) for left the eye, with a total of 11 (IQR 7-16) laser treatment 
sessions. Importantly, laser treatment alone was not taken as evidence of 
DME or PDR since severe NDRP (i.e. preproliferative DRP) is also an 
indication for laser photocoagulation 
8.4.2 FUNDUS PHOTOGRAPHS 
 
The fundus photographs taken for screening or documentation purposes as 
well as fluorescein angiographies were obtained from the participating study 
centers and scanned and stored in a digital archive (Table 3). The fundus 
photographs were available for 1 441/1 866 (78%) of the patients. The fundus 
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photographs were graded with the ETDRS-scale (94, 95). Approximately 3% 
of the photographs were judged ungradable due to poor image quality. The 
patients with photographs had been photographed on a median of 3 (IQR 1-
5) times per patient. The high percentage of fundus photographs increases 
the sensitivity of the study since retinal photography has been reported to be 
the most sensitive screening method for any diabetic retinopathy. The 
sensitivity is in the excess of 80% in detecting severe DRP. Ophthalmoscopy 
has less sensitivity but conversely a higher specificity (248). 
 
 
Table 3. Fundus photographs. The patients with photographs available (n=1 441 ) had 
been photographed on a median of 3 (IQR 1-5) times per patient. 
Photographic fields and their coverage Number 
1 x 45 2 024 
2 x 45 445 
1 x 60 or 1 x 50 1 296 
2 x 60 or 2 x 50 712 
30 degree 
(number of fields not specified) 
373 
Types of photographs Number 
Polaroid 748 
Colour photo 2 843 
Colour slide 73 
Grayscale 556 
Red-free 330 
FAG 219 
Digital photos 81 
Total 4 850 
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8.4.3 OPHTHALMIC RECORDS 
 
Ophthalmic records were obtained and scanned into a digital archive. The 
combination of the fundus photography with clinical examination gives a 
good sensitivity and specificity for the detection of severe DRP. The majority 
of the patients in this study had attended several screening examinations and 
1 441/1 866 (77%) had fundus photographs available. Practically all of the 
patients without fundus photographs had been examined by 
ophthalmologists, and only 9 patients had been examined by a diabetologist. 
The clinical fundus examination by an ophthalmologist is important because 
it has a good specificity as compared to the screening photographs (248) and 
because the stereoscopic fundus examination is a requirement for the 
detection of DME.  
8.4.4 GRADING OF DIABETIC RETINOPATHY SEVERITY  
 
The retinopathy severity scale produced in the ETDRS was used in this study 
to assess the severity of DRP in the fundus photographs (Table 4) (95). The 
ETDRS scale is not commonly used in clinical practice, or in the retinopathy 
screening, where the descriptions of the fundus changes resemble more the 
proposed international DRP severity scale (249). The proposed international 
severity scale is a derivative of the ETDRS scale and can, thus, be roughly 
compared to the ETDRS scale as shown in Figure 10. Some of the patients in 
this study did not have fundus photographs available, but instead they had 
verbal descriptions of clinical fundus examinations that could thus be 
approximated to numerical values in the ETDRS scale. 
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Table 4. The ETDRS retinopathy severity scale (95) 
Level Severity Definition 
10 DRP absent Microaneurysms and other characteristics absent 
14/15 
DRP 
questionable 
Microinfarcts, IRMA, haemorrhages, but no microaneurysms 
20 
Very mild 
NPDR 
Only microaneurysms  
35 Mild NPDR 
One of the following:   
 Microaneurysms and lipid exudates, microinfarcts, venous loops, 
questionable IRMA and venous beading (VB)  
 Haemorrhages and microaneurysms as in standard photograph 1 in 1-
4/4 quadrants 
43 
Moderate 
NPDR 
One of the following (not both) 
 Haemorrhages and microaneurysms > standard photograph1 in 4/4 
quadrants or ≥ standard photograph 2a ¼ quadrants  
 Mild IRMA in 1-3/4 quadrants 
47 
Moderately 
severe NPDR 
One of the following: 
 Both level 43 characteristics, or one of the following: 
o Haemorrhages and microaneurysms  ≥ standard photograph 
2a in 2-3/4 quadrants  
o Venous beading as in standard photograph 6a in ¼ quadrants  
o Mild IRMA in 4/4 quadrants  
i.e. 2-1-4- rule with one characteristic true 
53 
(53A-D) 
Severe NPDR 
One of the following: 
 Two or more level 47-characteristics (i.e. 2-1-4- rule with 2 
characteristics true)  
 Haemorrhages and microaneurysms ≥ standard photograph 2a in 4/4 
quadrants  
 Venous beading as in standard photograph 6a in 2-4/4 quadrants  
 Severe IRMA ≥ standard photograph 8b in 1-4/4 quadrants  
i.e. 4-2-1-rule with 1 characteristics true 
55 
(53E) 
Very severe 
NPDR 
Two of the following : 
 Haemorrhages and microaneurysms ≥ standard photograph 2a in 4/4 
quadrants  
 Venous beading as in standard photograph 6A in 2-4/4 quadrants  
 Severe IRMA ≥ standard photograph 8B in 1-4/4 quadrants  
i.e. 4-2-1-rule with 2 characteristics true  
61 Mild PDR 
NVE (Neovascularisation elsewhere) <0,5 Disk Area (DA) in 1-4/4 
quadrants 
65 Moderate PDR 
One of the following: 
 NVE (Neovascularisation elsewhere, more than 1 disc diameter 
distance from optic disc) < 0,5 DA in 1-4/4 quadrants and vitreous 
haemorrhage (VH) or preretinal haemorrhage (PRH) < 1 disc area  
 NVD (Neovascularisation at Disc) <standard photograph 10A (<0.25-
0.33 DA)  
 NVE ≥0.5 DA in 1-4/4 quadrants 
71/75 High-risk PDR 
One of the following: 
 NVD ≥standard photograph10a  
 NVE ≥0.5 DA or NVD<standard photograph 10A and vitreous 
haemorrhage (VH) or preretinal haemorrhage (PRH)  
 Vitreous haemorrhage (VH) or preretinal haemorrhage (PRH)  ≥1 DA 
(thus obscuring possible neovascularisation) 
81/85 
Advanced 
PDR  
Fundus partially obscured by vitreous haemorrhage and either new vessels  
ungradable or retina detached at the center of the macula 
90 Cannot grade Cannot grade even sufficiently for levels 81/85 
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Figure 11 The ETDRS and the proposed international retinopathy classifications with the 
terminology commonly used in clinical practise for different stages of retinopathy 
severity.  
The DME was assessed based on the fundus photographs and the 
descriptions in the ophthalmic files. The ETDRS study had two definitions 
for DME. The division was based on the distance of retinal thickening from 
the fovea. In the ETDRS, any retinal thickening within 1 disc diameter from 
the fovea was taken as evidence of DME. If the retinal thickening involved or 
threatened the center of the macula (even if visual acuity was not yet 
reduced), the retinal thickening would then be defined as CSME. CSME was 
defined 1) as the presence of retinal thickening at or within 500 μm of the 
center of the macula, or 2) hard exudates at or within 500 μm of the center of 
the macula if associated with thickening of the adjacent retina or zones of 
retinal thickening at least 1 disc area in size, at least a part of which is within 
1 disc diameter of the center of macula. The assessment of the CSME in the 
ETDRS was made by stereo contact lens biomicroscopy or stereo 
photography (250). Because of the complex nature of the CSME definition, 
an easier definition has been suggested which is also closer to the 
terminology and descriptions used by clinical ophthalmologists (249). The 
proposed international maculopathy severity scale can be approximated to 
the ETDRS definitions as shown in table 5 (249).  
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Table 5.  Classifications of diabetic macular edema (DME) 
 
Proposed international maculopathy classification 
None 
DME apparently 
present 
Mild DME Moderate DME Severe DME 
No apparent retinal 
thickening or hard 
exudates in the 
posterior pole 
Some apparent retinal 
thickening or hard 
exudates in the 
posterior pole 
Some retinal 
thickening or hard 
exudates in the 
posterior pole, but 
distant from the 
center of macula 
 
Retinal thickening or 
hard exudates 
approaching, but not 
involving the center 
of the macula 
 
Retinal 
thickening or 
hard exudates 
involving the 
center of the 
macula 
ETDRS maculopathy classification  
No DME 
DME but not clinically 
significant 
Clinically significant DME 
(CSME) 
Fluorescein leakage without retinal thickening 
Retinal thickening or hard 
exudates within 1 disc 
diameter of the fovea 
The presence of retinal 
thickening at or within 500 μm 
of the center of the macula or 
hard exudates at or within 500 
μm of the center of the macula 
if associated with thickening of 
the adjacent retina or zones of 
retinal thickening at least 1 disc 
area in size, at least part of 
which is within 1 disc diameter 
of the center of macula 
 
8.4.5 STATISTICAL METHODS 
 
The data are presented as means and SDs for continuous, normally 
distributed variables and CIs for estimates of cumulative risk, HRs and ORs. 
Medians and IQRs are given for non-normally distributed variables. SEs are 
given for mean differences and heritability estimates. Differences between 
two groups were tested with the t-test, or the Mann Whitney test. The 
differences between multiple groups were compared with one-way ANOVA 
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adjusted for multiple comparisons and the differences between proportions 
with either Kruskal-Wallis or Chi-square test. The trends in normally 
distributed variables were analysed with linear polynomial contrasts 
(ANOVA) and Jonckheere-Terpstra test in non-normally distributed 
variables. Spearman’s rho (rs) was used as a measure of correlation. The 
overall significance of a categorical risk factor in a regression model was 
tested with the Wald test. The Nelson-Aalen estimator was used to generate 
cumulative hazard curves shown in this thesis, and the associated stratified 
hazard-rate ratios and significance tests, controlling for time, were calculated 
by using a Mantel-Haenszel method. The regression models were compared 
with BIC (Bayesian information criteria) in studies III, IV and V. The main 
advantage of BIC is that the factors included in the regression have a high 
probability of being associated with the outcome variable. However, BIC is so 
stringent that some factors could be left out even if they actually are 
important. Most of the statistical calculations were performed with SPSS 15.0 
(SPSS, Chicago, IL, USA), Stata 11.2 (Statacorp, Texas, USA), or R open 
source software (www.r-project.org). In addition, special software as noted 
below was used for familial associations in study I and for competing risks 
assessment in study II. 
8.4.5.1 Study I 
 
The unadjusted intrafamilial associations were estimated by calculating ICC  
(intra-class correlations) for sibpairs. The FCOR-program of the SAGE-
software package (Case Western Reserve University, Cleveland, OH) was 
used with a uniform weighting scheme giving equal weights for each sibship 
regardless of the number of sib pairs within the sibships (251). Similarly, the 
correlations between ordinal ETDRS scores and DRP status were calculated 
with the FCOR-program using the same weighting scheme. The mean 
differences in current age and duration of diabetes between probands and 
siblings were calculated using a linear mixed model. In order to study the 
familial aggregation of PDR or any DRP three complementary analyses were 
used. First, the presence or absence of PDR in the proband was estimated as 
a risk factor for the corresponding condition in the other siblings. The 
familial risks were estimated with logistic regression models, adjusted for 
conventional risk factors, and fitted with generalized estimating equations 
using an exchangeable correlation structure to account for correlations 
within sibships (252). Second, to measure the degree of concordance within 
sibships, the intraclass correlation of durations of diabetes to the diagnosis of 
PDR was calculated in the 29 sibships in which two siblings had PDR. Third, 
the h2 of PDR was estimated by a liability threshold model as implemented in 
the SOLAR-software (SOLAR, Version 4.0.7. Southwest Foundation for 
Biomedical Research, San Antonio, TX) with HbA1c, mean arterial pressure, 
gender, and the duration of diabetes as covariates. The liability threshold 
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model is an extension of the variance components model to dichotomous 
traits, such as PDR (253). In the variance components model, the overall 
phenotypic variation is partitioned into individual variance components due 
to polygenic effects (multiple unmeasured genes under an additive variance), 
covariates (e.g. duration, gender, HbA1c, BP), and random environmental 
effects. The estimated h2 is defined as the ratio of the genetic variance 
component to the residual phenotypic variance, and it is an estimate of the 
familiality of the trait. The significance of the genetic component was 
determined by a likelihood ratio test. 
8.4.5.2 Study II 
 
Kaplan-Meier survival analysis was used to estimate the time without PDR, 
and Mantel-Cox logrank test to compare the survival distributions among 
different age at onset groups. The risk of PDR within the age at onset groups 
was estimated with a Cox proportional hazards model, controlling for 
clinically significant covariates. A previously published macro for SAS 
statistical software (SAS, Cary, NC, USA) was used to account for the 
competing risk of death (254).  
8.4.5.3 Study III 
 
As a normalised measure of variability, the coefficient of variation (CV) for 
the serially measured HbA1C was calculated as the ratio of intrapersonal SD 
and the mean to correct for larger SD because of higher absolute values of 
HbA1c (255).  The patients were then ranked into quartiles of HbA1c, 
variability (CV) in both subcohorts. Cumulative incidences for the laser 
treatment were calculated with a cumulative incidence function which 
accounts for the competing risk of death. The differences in cumulative 
incidences were tested with Gray’s test (256). As the cumulative incidences of 
death (n=32) were borderline significantly different (P=0.09, Gray’s test) in 
the various HbA1c variability quartiles, a recently published modification of 
Fine & Gray competing risks regression for clustered data (participating 
study centers) was used to calculate the risk of laser treatment during the 
follow-up (257). The Fine & Gray model takes into account the follow-up 
time (failure time) until the event of interest occurs, or the patients are 
censored without event, and the model also controls for clinically-significant 
covariates. The effect modification (i.e., whether the effect of a certain 
variable on the risk of PDR or laser treatment varied according to the level of 
another covariate) was tested for by adding corresponding interaction terms 
to the regression models. Pairwise first and second order interactions 
between the mean HbA1c, the CV (coefficient of variation), and the duration 
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of diabetes were studied. None of the interaction terms were significant. In 
addition, Schoenfeld residuals were plotted to confirm that the proportional 
hazards assumption was met. The model selection was then based on BIC in 
Fine & Gray regression. 
8.4.5.4 Study IV 
 
The cumulative incidence function was used in order to account for the 
competing risk of death, and the differences in cumulative incidences were 
tested with Gray’s test (256). As both cumulative incidences of CSME 
(P=0.0010, Gray’s test) and death (P=0.010, Gray’s test) differed 
significantly between various age at onset groups, the adjusted hazard ratios 
were calculated with Fine & Gray competing risks regression model. This 
model takes the duration of diabetes into account until the event of interest 
has occurred (258). In order to avoid overfitting the Gray & Fine regression 
model, the covariates were selected with BIC from a very large set of 
candidate models (258).  
8.4.5.5 Study V 
 
The failure times (survival) for the cumulative incidence function were 
calculated from onset of diabetes until death, PDR, or for the patients 
without events (censored) to the end of the DRP follow-up. The differences in 
the distributions of cumulative incidences were tested with Gray’s test (256). 
Secondly, the Cox regression model with a shared gamma frailty was used for 
calculating hazard ratios. A frailty is an unobservable random effect shared 
by subjects within a subgroup. Families with a large value of frailty will 
experience the event of interest at earlier times than families with small 
values of the random effect. Thus, the most “frail” individuals will get PDR 
early, and late survivors will tend to come from more robust families (259). 
The Cox regression model with a shared frailty was adjusted for certain a 
priori-selected potential risk factors such as HbA1c, sex, MAP, and the size of 
the sibship. The model selection was based on BIC. The Schoenfeld residuals 
were plotted to confirm that the proportional hazards assumption was met. 
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9 RESULTS 
The table 6 depicts the clinical characteristics of the study patients according 
to the retinopathy status. There was a significant overall effect of 
hyperglycaemia and BP on the risk of severe DRP and laser treatment 
throughout all studies. This is most clearly shown in the subset of patients 
from study III who were followed prospectively for the occurrence of the first 
laser treatment (n=1 459). These patients had a mean diabetes duration of 
16.9 (SD 10.4) years before the start of the 5.2 (SD 2.2) years follow-up 
period. The patients had their HbA1c values measured on a median of 10 (IQR 
3-17) times. The mean HbA1c was then ranked into quartiles. The mean HbA1c 
was 10.0 (SD 0.9) %, 8.6 (SD 0.2) %, 7.9 (SD 0.2)%, and 6.9 (SD 0.5)% from 
the highest to the lowest quartiles respectively. The cumulative incidences of 
laser treatment, accounting for the competing risk of death, were 
significantly higher when the mean HbA1c was high (Figure 11). The highest 
mean HbA1c quartile had HR 4.3  (95% CI 2.6-7.2, p<0.001)  as compared to 
the lowest mean HbA1c quartile when adjusted for the baseline mean arterial 
BP (p<0.001) in a Fine & Gray competing risks regression accounting for the 
competing risk of death. Because of the constant association of BP and 
hyperglycaemia with the risk of severe DRP, they were used as explanatory 
covariates in all subsequent regression models. 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 The cumulative incidence of laser treatment in different quartiles of the mean HbA1c 
(P<0.001, Gray’s test). 
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Table 6. The clinical characteristics of patients according to retinopathy status, 
male/female 992/874. Of the patients with  laser-treated diabetic macular edema 
(DME) 250/346 (72%) had also had proliferative retinopathy (PDR). Of the 
patients in PDR group, none had been treated for DME. 
 
The values are expressed as means ± standard deviations, or medians (IQR=interquartile 
range). P-value for trend, P <0.05*. MAP= Mean Arterial Pressure, BMI= Body Mass Index,  
hsCRP = high sensitivity C-reactive protein, WHR= Waist-to-Hip Ratio,  ASA=Aspirin 
(Acetylsalicylic Acid), AHT= Antihypertensive Treatment, MSBP =Mean systolic Blood 
Pressure, MDBP =Mean Diastolic Blood Pressure 
Retinopathy 
No 
retinopathy 
(n=445) 
NPDR 
(n=690) 
Laser-treated 
DME (n=346) 
PDR (n=385) 
All Patients 
(n=1866) 
Duration of diabetes 
(years) * 
13.5 ±8.5 24.6 ±9.6 29.8 ±8.5 34.4 ±9.1 24.9 ±11.6 
Age (years) * 32.8 ±11.4 38.7 ±11.4 44.9 ±10.4 44.4 ±10.4 39.6 ±11.9 
Age at onset (years) * 19.1 ±10.4 14.1 ±9.3 15.1 ±9.4 10.1 ±6.6 14.7 ±9.6 
HbA1c (%)* 8.1 ±1.4 8.5 ±1.4 8.9 ±1.5 8.7 ±1.5 8.5 ±1.5 
MSBP (mmHg) * 128 ±15 131 ±17 141 ±21 143 ±20 134 ±19 
MSDP (mmHg) * 77 ±9 79 ±9 82 ±11 83 ±10 80 ±10 
MAP (mmHg)* 94 ±10 97 ±11 102 ±13 103 ±12 97 ±12 
AHT (%)* 10.8 28.1 70.3 74.3 41.4 
ASA treatment (%)* 3 8 18 27 12 
Diabetic nephropathy 
(%)* 
1 9.0 56 63 27 
Triglycerides (mmol/l)* 
0.9  
(IQR 0.7-1.2) 
1.1  
(IQR .7-1.3) 
1.2  
(IQR 0.9-1.8) 
1.2  
(IQR 0.9-1.7) 
1.0  
(IQR 0.7-1.5) 
Total Cholesterol* 
(mmol/l) males 
4.7 ±0.9 4.8 ±0.9 5.3 ±1.1 5.2 ±1.1 5.0 ±1.0 
HDL Cholesterol* 
(mmol/l) males 
1.5 ±0.4 1.5 ±0.4 1.4 ±0.4 1.4 ±0.4 1.4 ±0.4 
HDL Cholesterol* 
(mmol/l) females 
1.8 ±0.4 1.8 ±0.5 1.7 ±0.6 1.6 ±0.4 1.7 ±0.5 
Statin treatment (%)* 3 8 18 17 11 
WHR males* 0.89 ±0.7 0.90 ±0.7 0.95 ±0.8 0.94 ±0.7 0.92 ±0.8 
WHR females* 0.80 ±0.06 0.81 ±0.06 0.83 ±0.07 0.84 ±0.07 0.82 ±0.07 
BMI* 24.5 ±3.4 25.2 ±3.4 25.7 ±4.0 25.6 ±4.1 25.2 ±3.7 
hsCRP(mmol/l) * 
1.5  
(IQR 0.9-3.1) 
2.0  
(IQR 1.2-4.3) 
2.4  
(IQR 1.4-5.3) 
2.5  
(IQR 1.6-5.4) 
2.1 
(IQR 1.2-4-7) 
Mortality (%)* 
(until 24.3.2009) 
2 5 21 25 11 
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9.1 STUDY I:  HERITABILITY OF PROLIFERATIVE 
DIABETIC RETINOPATHY IN TYPE 1 DIABETES 
 
There were a total of 396 patients in the FinnDiane study, who came from 
sibships with at least two siblings with type 1 diabetes. The records of 
treatment and follow-up could be obtained for 369/396 (93%) of these 
patients. The male/female ratio was 202/167 and the mean diabetes duration 
25.9±11.8 years. The mean duration from the onset of diabetes to PDR was 
20.9±7.5 years, and the mean age at onset of diabetes was 14.3±10.2 years. 
PDR was found in 115/369 patients (31%). In 8/115 (7.0%) patient’s PDR was 
discovered at their first examination by an ophthalmologist, and there were 
no previous fundus examinations for these patients without PDR. The other 
patients had all had at least one ophthalmic examination on a median of 1.0 
(IQR -2.2 – (-) 0.4) years prior to the diagnosis. There were a total of 48/168 
(29%) probands (the oldest sibling) with PDR and 61/182 (34%) of the 
younger siblings who also had PDR. The siblings of probands with PDR had a 
higher unadjusted cumulative risk of PDR HR 2.2 (95% CI 1.3-3.6, P = 0.002, 
Mantel Haenszel Chi-square test) when compared to siblings of probands 
without PDR (Fig. 13).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 The cumulative hazard estimates (Nelson-Aalen) of proliferative diabetic retinopathy 
(PDR) in 182 siblings stratified according to whether the proband has PDR or not. 
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The sibships with PDR in the probands had a significantly higher mean 
arterial BP, 104 mmHg (±13) vs. 99 mmHg (±11) (P<0.001, t-test), as 
compared to the sibships without PDR in the proband (Fig. 14) 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
 
 
 
Figure 14 Mean arterial blood pressure (MAP) in sibships (P<0.001, t-test) 
The sibships with PDR in the proband also had a higher HbA1c, 8.8±1.5 % vs. 
8.4±1.6 % (P<0.03, t-test) than sibships without PDR in the proband (Fig. 
15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 HbA1c in sibships with or without proliferative retinopathy (PDR) (P=0.03, t-test) 
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Because of these similarities in clinically significant risk factors, the risk 
estimate was calculated cross-sectionally in a logistic regression model with 
the duration of diabetes, HbA1c, and the mean arterial BP as covariates. The 
heritability was estimated in a variance component model in which the 
proportion of variance attributable to all covariates (HbA1c, duration, and 
BP) was 0.23 (Kullback-Leibler R2). PDR in the probands (48/168) was a 
significant risk factor for PDR in later-born siblings 61/182 (34%) after the 
adjustment for the similarities in the above mentioned risk factors OR 2.76 
(1.25 - 6.11, P=0.01). The 29 proband-sibling pairs, in which both members 
had PDR were concordant for the survival time without PDR (intra class 
correlation = 0.47 [0.14-0.71], P=0.004). The heritability of PDR was 
h2=0.52 (±0.31, P<0.05) as adjusted for mean arterial BP, HbA1c, and 
diabetes duration. The sex was non-significant (P>0.1).     
9.2 STUDY II: AGE AT ONSET AND THE RISK OF 
PROLIFERATIVE RETINOPATHY  IN TYPE 1 
DIABETES 
 
The effect of age at onset of type 1 diabetes on the long-term risk of PDR was 
studied in a cohort of 1 117 patients, male/female 596/521. The mean age at 
onset of type 1 diabetes was 13.7±8.5 years, and the mean duration of 
diabetes 25.0±11.4 years. The longest median duration to development of 
PDR was 22.2 (IQR 19.1-26.9) years in the 0-4 age at onset group (n= 79), 
whereas the shortest was 18.2 (IQR 15.0-24.3) years in the 5-14 age at onset 
group (n= 212). In the 15-40 age at onset group the median duration to PDR 
was 20.0 (IQR 16.0-27.2) years (n= 76) (Fig. 16). 
 
 
                
 
 
 
 
 
 
 
 
 
 
Figure 16 The time to diagnosis of proliferative retinopathy (years) in different age at onset 
groups (P< 0.001, Anova) 
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The highest proportion of patients with PDR 47% was observed in the age at 
onset group of 0-4 years, the second highest in the age at onset group of 5-14 
years 39%, and the lowest in the age at onset group 15-40 years 19%. 
Altogether, PDR was found in 367/1117 (33 %) patients. The differences in 
the incidence as well as the median survival times resulted in the lowest 
cumulative risk of PDR for the age at onset group of 15-40 years (Fig. 17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 The cumulative hazard estimates (Nelson-Aalen) of proliferative diabetic retinopathy 
(PDR)  in 1117 patients stratified according to the age at onset. (P=0.007, Mantel-
Haenszel Chi-square test). 
Despite the initially lower risk for the youngest age at onset group, the long-
term cumulative risk was similar in the age at onset group 0-4 years and the 
5-14 years (Fig. 17). Patients with PDR had the highest mortality 20.4%, the 
highest HbA1c 8.7 ±1.5%, and the longest duration of diabetes 33.1±9.1 years. 
The patients in the age at onset group of 15-40 years had the highest 
proportion (21%) of patients with C-peptide concentrations above the 
detection limit of 0.033 nmol/l. A total of 99 of the 1 117 patients (8.9%) had 
died during the follow-up. Of these, 75/99 (75.8%) had been diagnosed with 
PDR. With such a long follow-up time, a potentially important issue is the 
competing risk of death. The outcomes from the Kaplan-Meier or the Cox-
regression analysis did not change if the cumulative risk of death was taken 
into account using a previously  published SAS macro (254). The risk of PDR, 
adjusted for HbA1c, BP, sex, and BMI, was the highest in the age at onset 
groups of 5-14 years, HR 1.90 (95% CI 1.45–2.48, p<0.001) as contrasted to 
the age at onset group of 15-40 years who had the lowest risk. Similarly, 
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patients with the age at onset between 0-4 years had a higher adjusted risk of 
PDR with a HR of 1.6 (95% CI 1.16-2.23, p=0.002) as compared to the age at 
onset group 15-40 years. BMI and sex were nonsignificant in this model. As 
for the other covariates, the risk of PDR increased 15% with every unit 
increase in HbA1c percentage with a HR of 1.15 (95% CI 1.07-1.23, p<0.001), 
and 3% with every 1 mmHg increase of the mean arterial BP with a HR of 
1.03 (95%1.02-1.04, p <0.001).  
There may also be a confounding cohort-effect in the present study, since 
the oldest patients may have a worse prognosis than the younger ones (149). 
The data were tested for such a cohort effect in two ways. The first was to use 
the year of the onset of diabetes as a continuous variable in the Cox-
regression model. The other was to use the decade of the onset of diabetes as 
a categorical variable. Both of these variables were statistically non-
significant in this model (P=0.74 for year of onset and P=0.72 for decade of 
onset, Wald test), and they did not alter the overall significance for the 
categorical variable age at onset. 
9.3 STUDY III: HbA1C VARIABILITY INCREASES THE 
RISK OF RETINOPATHY REQUIRING LASER 
TREATMENT IN TYPE 1 DIABETES 
 
The effect of HbA1c variability on DRP progression was studied in a total of     
2 019 patients, male/female 995/1 024. The patients were divided into two 
partially overlapping subcohorts with either verified first laser treatment 
(n=1459) or DRP severity and progression graded from ophthalmic records 
with the ETDRS scale (n=1 346) (Fig. 10).  The mean duration of diabetes 
was 22.9±11.9 years with a mean age at onset 15.3±9.2 years. A median of 10 
(IQR 3-18) HbA1c measurements were recorded per patient. The 
intrapersonal mean of serially measured HbA1c was 8.4±1.2 %. There was a 
clear correlation between the HbA1c measured at the baseline and the mean 
of serial HbA1c measurements (rs =0.77, P< 0.001). The mean HbA1c also 
correlated positively with the intrapersonal SD of the HbA1c values (rs=0.39, 
P<0.001). Thus, the patients with the highest mean HbA1c values had the 
highest variation of their HbA1c values. Also the number of HbA1c 
measurements correlated positively with the intrapersonal SD of the mean 
HbA1c (rs=0.32) which could have resulted from the repeated attempts by the 
attending clinicians to improve the glycaemic control of the patients with 
high HbA1c values. The regression models were, therefore, adjusted for both 
the number of HbA1c measurements and the mean HbA1c. There were 
progressively higher HbA1c values from the 1st to the 4th quartile as shown in 
Figure 18 for the laser treatment subcohort. Total cholesterol, BP and BMI 
were no different in the higher quartiles of variability.  
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There were a total of 1 459 patients with no previous laser treatment and 
with prospective follow-up data after the FinnDiane baseline visit for a 
period of 5.2±2.2 years. Of these patients, 74 had their first laser treatment 
during the follow-up period. The estimated 5-year cumulative incidences of 
laser treatment, accounting for the competing risk of death, were 19.1 % 
(95%CI 14.6-23.9) in the 4th quartile of HbA1c variability, 11.8 % (95%CI 8.5-
15.7) in the 3rd quartile, 8.8 % (95%CI 5.9-12.4) in the 2nd quartile, and 9.5 % 
(95%CI 6.5-13.3) in the 1st quartile (P< 0.001, Gray’s test). The patients with 
CV above the median had a higher unadjusted risk of laser treatment HR 1.4 
(95%CI 1.03-1.9, P<0.03, Mantel-Haenszel Chi-square test) as compared to 
the patients with CV below the median (Fig. 19).        
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 Mean HbA1c in different quartiles of CV (coefficient of variation) in the subcohort of 
laser-treated patients (P<0.001, Anova) 
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Figure 19 The cumulative hazard estimates (Nelson-Aalen) of laser treatment in 1 459 
patients stratified according to coefficient of variation (CV) below or above the 
median (P < 0.03, Mantel-Haenszel Chi-square test). 
In a Fine & Gray competing risks regression model, adjusted for the baseline 
duration of diabetes, renal status, mean HbA1c, MAP, sex, and the number of 
HbA1c measurements, and also accounting for possible correlations within 
the study centers, the CV quartile was a significant overall risk factor for laser 
treatment (P=0.04, Wald test). The highest adjusted risk of laser treatment 
HR 1.6 (95%CI 1.1-2.5, P=0.02) was seen in the 4th quartile as compared to 
the 1st quartile of CV.  
The specific indications for each individual laser treatment were verified 
from ophthalmic records and fundus photographs for a subcohort of 1 346 
patients. The associations between the conventional risk factors, HbA1c 
variability, and PDR were further analysed in this subcohort (Fig.10). Of 
these patients, 434/1 346 (32 %) had been diagnosed with PDR. Patients with 
PDR had a lower than average age at onset of type 1 diabetes (11.0±7.2 years, 
P<0.001, t-test), higher than average mean HbA1c (8.7±1.3 %, P<0.001, t-
test), higher mean arterial BP (102.2±11.9 mmHg, P<0.001, t-test), higher 
BMI (25.6±3.9 kg/m2, P<0.001, t-test), and longer duration of diabetes 
(33.3±9.0 years, P<0.001, t-test). Furthermore, patients with PDR had 
higher than average values of CRP (2.4 IQR 1.4-4.9 mmol/l, P<0.001, Mann-
Whitney test), and triglycerides (1.2 IQR 0.9-1.6 mmol/l, P<0.001, Mann-
Whitney test). In a Fine & Gray regression model, the HbA1c variability 
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quartile (CV) was significantly associated with PDR (P=0.003, Wald test). 
The 4th quartile of HbA1c variability (CV) had the highest HR 1.7 (95% CI 1.3, 
2.2, P<0.001), as contrasted to the 1st quartile. For the other clinically 
relevant covariates, the mean HbA1c HR 1.2 (95% CI 1.1, 13, P<0.001) and BP 
with a HR of 1.02 (95% CI 1.01, 1.03, P<0.001), were significantly associated 
with PDR. However, male sex was a nonsignificant factor with a HR of 1.2 
(95% CI 0.9, 1.3, P=0.5). The patients’ highest attained ETDRS score and the 
renal status showed a significant correlation (rs = 0.64, P<0.001). Because of 
this, the renal status was not included in the Fine & Gray regression model 
for PDR. However, if only patients with no nephropathy (normal UAER, or 
microalbuminuria, n=969) were included, the HbA1c variability above the 
median was still associated with PDR with a HR of 1.4 (95% CI 1.01, 2.0, P= 
0.04). 
9.4 STUDY IV: HIGHER AGE AT ONSET OF TYPE 1 
DIABETES INCREASES RISK OF MACULAR EDEMA 
The effect of age at onset of type 1 diabetes was studied in a cohort of 1 354 
patients (male/female 727/627). The mean age at onset of type 1 diabetes 
was 14.1±8.7 years and mean duration of diabetes 24.6±11.6 years. CSME 
was diagnosed in 242 patients (17.9 %) and PDR in 425 patients (31.4 %). 
PDR and CSME showed a significant overlap as the majority (73 %) of the 
patients with CSME had also been diagnosed with PDR at some point. The 
longest mean duration of diabetes to CSME was 23.6 ±6.4 years in the 0-4 
age at onset group, whereas the shortest was 17.6 ±6.5 years in the 15-40 age 
at onset group. The oldest age at onset group had also the highest cumulative 
incidence of CSME. At 30 years of diabetes duration, the estimated 
cumulative incidences of CSME were 17.0% ( 95% CI 10.7–24.5) in the age at 
onset group 0-4 years, 27.4% (95% CI 22.7-32.4) in the age at onset group 5-
14 years, and 34.1% (95%CI 27.3-41.0) in the age at onset group 15-40 years 
(P=0.001, Gray’s test).  The highest unadjusted cumulative risk of CSME was 
seen in the oldest age at onset group (Fig. 20). 
Patients with CSME had higher HbA1c (8.8±1.5 %, P<0.001, t-test), higher 
triglycerides (1.2 IQR 0.9-1.7 mmol/l, P<0.001, Mann-Whitney test) and 
total cholesterol (5.3±1.1 mmol/l, P<0.001, t-test) (Fig. 21 and 22), higher 
proportion of patients with nephropathy 47% (P<0.001, Chi-square test), 
and lower eGDR 4.1±1.5  mg• kg-1•min-1  (P<0.001, t-test) than patients 
without CSME. The adjusted risk of CSME was calculated in a competing 
risks regression model (Fine&Gray), for which the covariates were selected 
with BIC. The covariates included were the age at onset group, ETDRS-score, 
HbA1c, and total cholesterol. The onset of diabetes after 15 years of age 
increased the risk of CSME the most, HR being 3.72 (95% CI 2.35–5.89, 
p<0.0001) as contrasted to the age at onset group of 0-4 years. Also, the 
patients with age at onset between 5-14 years had a higher risk of CSME with 
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a HR of 1.89 (95% CI 1.22-2.91, P=0.004) as compared to the youngest age at 
onset group. Other significant risk factors were the ETDRS score with a HR 
of 1.04 (95% CI 1.03-1.05, P<0.001), HbA1c HR 1.12 (95% CI 1.02-1.23, 
P=0.016), and total cholesterol HR 1.19 (95% 1.04-1.37, P=0.013). The 
patients’ highest attained ETDRS-score and the renal status showed a strong 
correlation (rs = 0.64, P<0.001). However, the nephropathy status and/or BP 
reduced the goodness of fit (BIC) of the regression model and were, thus, not 
included in the regression model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20 The cumulative hazard estimates (Nelson-Aalen) of clinically significant macular 
edema (CSME)  in 1354 patients stratified according to the age at onset group (P< 
0.001, Mantel-Haenszel Chi-square test). 
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Figure 21 Total cholesterol in patients with or without clinically significant macular edema 
(CSME) (P < 0.001, t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
Figure 22 Total cholesterol in different retinopathy groups (P = 0.001, Anova). 
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the competing risk of death increased with the duration of diabetes and was 
the highest in the oldest age at onset group. A total of 130/1 354 patients 
(9.6%) had died. Of these 45/130 (34.6%) had been diagnosed with CSME. 
The cumulative incidence estimates and regression models, therefore, 
accounted for the competing risk of death. An additional and potentially 
important confounding effect may be the improvement in medical and 
ophthalmic care that is gradually improving the long-term prognosis of DRP 
(152). The data were tested for such a time dependent confounding effect in 
two ways. The year of the onset of diabetes was used either as a continuous 
variable in a competing risks regression model, or the decade of onset of 
diabetes as a categorical variable. Neither of these changed the overall 
significance or magnitude of the effect of age at the onset as a risk factor for 
CSME. 
9.5 STUDY V: THE RISK OF PROLIFERATIVE 
RETINOPATHY IN SIBLINGS WITH TYPE 1 
DIABETES 
 
The effect of the age at onset of type 1 diabetes within sibships was studied in 
the same patient cohort as the effect of heritability in study I. As a difference 
to study I, where the oldest sibling was the proband, the sibling first 
diagnosed with type 1 diabetes was designated as the proband in study V. 
Overall, PDR was diagnosed in 115/369 (31%) of the patients. The number of 
patients with PDR was higher in the probands as compared to the later 
affected siblings (36% vs. 27%, P=0.05, Chi Square), and the probands also 
had a significantly longer duration of  diabetes as compared to their later 
affected siblings (30.3 [IQR 21.8-29.2] vs. 19.6 [IQR 13.2-29.4] years, 
P<0.001, Mann-Whitney). The median age at onset of type 1 diabetes was 8.4 
(IQR 4.2-13.3) years in probands, whereas the median age at onset of type 1 
diabetes was 16.9 (IQR 10.2-27.8) years in the later affected siblings 
(P<0.001 Mann-Whitney). If the cut-off value for puberty was arbitrarily 
chosen to be at age 12 years for males and at age 11 for females, the difference 
in the age at onset resulted in a significantly longer median prepubertal 
diabetes duration for the probands as compared to the later affected siblings 
(P<0.001, Mann-Whitney) (Fig 23). 
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Figure 23 The probands had a longer prepubertal diabetes duration than the later affected 
siblings (P < 0.001, t-test) 
The cumulative incidence estimates for PDR, accounting for the 
competing risk of death, were 21% (95% CI 15-27) in probands and 26% (95% 
CI 19-35) in later affected siblings at 20 years of diabetes duration, and the 
30 years cumulative incidences were 37% (95% CI 29-45) and 53% (95% CI 
40-64) (P=0.05, Gray’s test) respectively. The overall cumulative incidence of 
death was no different between probands (0%) and later affected siblings 2% 
(95% CI 0-7) after 30 years of diabetes duration (P=0.3, Gray’s test). The 
unadjusted cumulative risk was higher in the probands with a HR of 1.5 (95% 
CI 1.03-2.1, P=0.04, Mantel-Haenszel Chi-square test) (Fig. 24). When 
adjusted for the duration of diabetes, HbA1c, MAP, male gender, age at onset 
of type 1 diabetes, and the size of the sibship, the later affected siblings had a 
moderately higher risk of PDR as compared to the probands with a HR of 
1.76 ( 95%CI 1.13-2.75), P=0.01). 
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Figure 24 The cumulative hazard estimates (Nelson-Aalen) of proliferative diabetic retinopathy 
(PDR)  in siblings stratified according to the onset of type 1 diabetes (P = 0.04, 
Mantel-Haenszel Chi-square test). 
If prepubertal years were omitted, the cumulative incidences of PDR were no 
different in probands and later affected siblings (P=0.6, Mantel-Haenszel 
Chi-square test) (Fig 25). 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25 The cumulative hazard estimates (Nelson-Aalen) of proliferative diabetic retinopathy 
(PDR) in siblings stratified according to the onset of type 1 diabetes without the 
prepubertal diabetes duration (P = 0.6, Mantel-Haenszel Chi-square test). 
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Similarly, in the regression models in which the prepubertal diabetes 
duration was omitted, the effect of proband became nonsignificant. However, 
in all the regression models in which the prepubertal diabetes duration was 
taken into account, the effect of the proband was significant. The inclusion of 
prepubertal diabetes duration also clearly improved the fit of the regression 
model as assessed with the BIC. 
Many of the patients in this study were diagnosed with diabetes already in 
the 1970’s. As a confounding effect, the patients diagnosed with diabetes in 
the 1970’s may have a worse prognosis than the patients diagnosed at the end 
of the 1980’s due to the improvement of medical care of diabetes and DRP 
(152). The data were tested for this confounding effect by including the birth 
year as a continuous variable in the regression models. The birth year was 
nonsignificant (P=0.6, Wald test) and it did not change the overall 
significance or magnitude of the effect for the probands.  
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10 DISCUSSION 
10.1 OVERALL STUDY DESIGN, STRENGTHS AND 
WEAKNESSES 
The FinnDiane study is an observational study which has recruited a large 
number of type 1 diabetes patients from different levels of health care, 
including primary health care centers and university hospitals. The patient 
sampling frame can be considered geographically representative of type 1 
diabetes in Finland (Fig. 9). The enrolled patients are well characterized 
regarding their medical history and the presence or absence of any diabetic 
complications. There are, however, a few potential concerns in the study 
design that need to be taken into account.  
The FinnDiane study has many independent study centers which could 
cluster the data. The statistical models were, therefore, calculated with or 
without adjusting for correlations within study centers in study III. All these 
models yielded practically identical results and, thus, indicated no significant 
clustering within the data. Another potential problem in the patient data is 
that the focus in the FinnDiane has been in the study of diabetic nephropathy 
which could have resulted in overrepresentation of microvascular 
complications in the FinnDiane patients. The FinnDiane patients may also 
overrepresent central and university hospitals since all of them are included 
in the FinnDiane and only 11% of the primary health care centers are 
involved, although most of the diabetes patients are treated in the primary 
health care system. However, the proportion of patients with PDR in this 
study was comparable to a previous population-based assessment of PDR in 
a sample of 1 067 patients in Finland (260). There is also a comprehensive 
screening system for DRP in the primary health care system which covers 
practically all of the diabetes patients and provides an easy access to the 
fundus photographs. This has balanced the patient sampling frame by 
providing a large number of patients without DRP and/or with milder 
degrees of DRP. The fundus photography has been used as the primary 
screening method for a more than 20 years, and a high percentage of patients 
with diabetes in Finland are undergoing regular fundus photography since 
the national guidelines for the screening of diabetic DRP were 
published already in 1992 and updated in 2006 (246, 247). These guidelines 
emphasized fundus photography as the preferable screening method (261). 
The majority of the patients in this study had attended several screening 
examinations. Many were examined and treated by ophthalmologists and 
eventually 1 441/1866 (77%) had fundus photographs available. Practically all 
of the patients without fundus photographs had been examined by 
ophthalmologists, and only 9 patients had been examined by a diabetologist. 
Retinal photography has been reported to be the most sensitive screening 
  77 
method for DRP. The sensitivity is in excess of 80% in detecting PDR (248). 
Ophthalmoscopy has less sensitivity, but conversely a higher specificity. It 
provides good results in the hands of trained professionals such as 
ophthalmologists and diabetologists (248). Fundus photography together 
with clinical fundus examination is, thus, a good combination of sensitivity 
and specificity. One possible limitation of the study may be the lack of a 
standardised fundus photography protocol. The majority of the fundus 
photographs were taken for screening purposes with quite heterogeneous 
methods. However, if severe NPDR or PDR was suspected based on the 
screening photographs, the patients were referred to an ophthalmologist for 
a clinical fundus examination. Furthermore, the 12-step ETDRS scale was 
used for a significant outcome only in study number IV where the risk of 
macular edema was adjusted for the ETDRS grade. The outcome of interest 
was PDR in all the other studies. 
The diagnosis of CSME was based on the ophthalmologist’s clinical 
decision to laser treat the patient in order to reduce DME. The detection of 
DME can be done clinically with biomicroscopy, or the retinal thickening can 
be detected from stereoscopic fundus photographs. Both of these methods 
have been shown to be reliable in the assessment of CSME (250). However, 
the subsequent clinical decision as to which areas need laser treatment and 
how much may show variation (262). It has been shown that the DME 
photocoagulation treatment threshold and dosage of laser spots differ 
depending on whether thickness assessments are based on stereoscopic slit-
lamp biomicroscopy or OCT. In addition, retinal specialists differ in the 
number and placement of planned laser spots even when given identical 
information concerning CSME and treatable lesions. This variability in the 
photocoagulation treatment could have led to differences in the clinical 
course of CSME (262).  
10.2 FAMILIAL FACTORS IN THE DEVELOPMENT OF 
DIABETIC RETINOPATHY 
10.2.1 FAMILIAL CLUSTERING OF PDR IN TYPE 1 DIABETES 
 
There was familial clustering of PDR in patients with type 1 diabetes, which 
could not be accounted for by conventional risk factors. Previous studies 
have been able to show familial clustering of severe NPDR in families with 
type 2 diabetes, (205, 206) and in families with a mixture of both type 1 and 
type 2 patients (207). However, no studies have so far given estimates for the 
familial risk of PDR. The estimated heritability of PDR was h2 = 0.52 (SE 
0.31, P<0.05), and the intraclass correlation of survival time without PDR 
0.47 (0.14-0.71, P=0.004). If the oldest sibling had PDR, the adjusted risk of 
PDR was OR 2.76 (1.25–6.11, P=0.01) for the sibling later affected with type 1 
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diabetes. A heritability estimate of 25% for PDR in type 2 diabetes was 
reported only a month after the publication of study I (208). The estimated 
25% heritability fits within the fairly wide SE of the present study and is, 
thus, in line with the results obtained here.  The 25% heritability was 
calculated in patients with type 2 diabetes, who may have a different genetic 
background and set of risk factors for DRP progression as compared to type 1 
diabetes patients. Another fact supportive of the findings of the present study 
is the comparable familial clustering of diabetic nephropathy (263). Diabetic 
nephropathy is a microvascular complication that is closely related to DRP 
(264). In a previous study regarding diabetic nephropathy, roughly 50% of 
the risk could not be attributed to the familial clustering of conventional risk 
factors (265).  As there is a close correlation between severe DRP and 
nephropathy it is conceivable that the two could have a common genetic 
background. 
10.2.2 GENETIC SUSCEPTIBILITY TO PDR 
 
It has been observed that severe DRP appears to have an inherent 
momentum of progression that, by time, leads to an almost linear increase in 
the incidence of PDR (130). The worsening of DRP continues even after an 
improvement of glycaemic control (159, 266), and the more severe the DRP 
is, the longer the delay before a beneficial effect of improved glycaemic 
control is observed (159). It is possible that this inherent momentum may at 
least partially be determined by genetic factors. The heritability estimates 
obtained from this study and from other studies are typical of a polygenic 
genetic component. It is of note, that some risk factors that are considered 
environmental, such as BP and HbA1c, also appear to be determined at least 
in part by genetic factors. In fact, it has been noted that a single HbA1c-
measurement offers a fair estimate of the glycaemic control during the 
previous ten years in type 1 diabetes patients (267). This could be a reflection 
of the predictive value of biological, between-individual variations in HbA1c, 
which is distinct from the mean blood glucose, and which is significantly 
determined by a genetic component (268, 269). In this study, both single 
measured HbA1c and BP were significant risk factors in the logistic regression 
and heritability calculations. Increased BP is considered to be a multifactorial 
trait with an estimated genetic contribution in the range of 30-50 % (270). 
Although both HbA1c and BP may have a significant familial component they 
are not likely to be the main factors behind the familial clustering of PDR. It 
has been shown in a simulation study that familial clustering of two additive 
environmental risk factors only leads to a slight excess in the clustering of a 
disease among the siblings (271). Therefore, it is unlikely that the degree of 
familiality observed in this study is the result of familial clustering of 
glycaemic control and BP alone. 
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Despite the apparent genetic contribution to DRP, attempts to find 
evidence for an involvement of any major loci in DRP have so far turned out 
inconclusive. Four genome wide-scans have offered suggestive evidence of a 
linkage, but on a number of different chromosomes in patients with type 2 
diabetes (209-212). The associations with various biologically relevant 
candidate genes have also  been extraordinarily difficult to replicate (213, 
214). This is not surprising because the heritability estimates imply a 
multifactorial inheritance with probably a modest risk increase or decrease 
from any single gene. 
10.2.3  THE SIBLINGS FIRST AFFECTED WITH TYPE 1 DIABETES 
HAVE A YOUNGER AGE AT ONSET  
 
The siblings first affected with type 1 diabetes were significantly younger at 
the onset of diabetes as compared to their later affected siblings, which is in 
line with previous studies (26-28). A possible biological explanation for this 
could be a simultaneous environmental trigger within sibships. The onset of 
diabetes has been associated, for example, with certain viral infections 
caused by enteroviruses. Thus, the older age at onset for the later affected 
siblings within the sibships could be related to a trigger that simultaneously 
initiates an autoimmune response in both the younger and the older siblings 
(272). Those siblings that are genetically or environmentally most susceptible 
to diabetes will then manifest type 1 diabetes at an earlier age. In addition to 
viral infections, there are likely to be other environmental risk factors that 
may, over time, interact with the susceptibility genes and modify their 
penetrance. It has been noted that the risk of diabetes decreases with higher 
birth order of the children in larger sibships, but the studies have also 
suggested that this risk reduction is modified by a complex interplay between 
birth order and maternal age at delivery (23, 24). There has also been an 
overall trend of diabetes onset at a younger age in the general population and 
this could have some importance within the sibships as well (273), although 
such a cohort effect was not observed in this study. 
10.2.4  AGE AT ONSET OF TYPE 1 DIABETES AS A RISK FACTOR 
WITHIN SIBSHIPS 
 
The siblings first affected by type 1 diabetes had a better long-term prognosis 
with regards to the development of PDR as compared to their later affected 
siblings. The cumulative incidence estimates for PDR, accounting for the 
competing risk of death, were 21% (95% CI 15-27) in the probands and 26% 
(95% CI 19-35)% in the later affected siblings at 20 years of diabetes duration 
and the respective 30 years incidences were 37% (95% CI 29-45) and 53% 
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(95% CI 40-64), (P=0.05, Gray’s test). The risk of PDR adjusted for 
conventional risk factors, the age at onset, and sibship size, was higher in the 
later affected siblings with a HR of 1.76 (95% CI 1.13-2.75,  P=0.01) as 
compared to their probands. 
The probands had mainly a prepubertal onset of diabetes whereas the 
later affected siblings had a postpubertal onset. If only postpubertal duration 
of diabetes was taken into account, the effect of the proband in the regression 
model was nonsignificant (Fig. 24 and 25). This suggests that the longer 
prepubertal duration of diabetes for the probands may explain the better 
long-term prognosis. It has previously been suggested that the prepubertal 
duration of diabetes contributes only minimally to the long-term risk of DRP 
(200). However, the exclusion of the prepubertal duration produced a clearly 
worse fit for the model (BIC) indicating that the prepubertal years indeed 
contribute significantly to the risk of PDR. The present study, thus, indicates 
that the prepubertal years are significant for the long-term prognosis and 
may modify the long-term prognosis even within sibships. The risk difference 
of diabetes onset before and after 15 years of age may also be related to the 
fact that the onset of type 1 diabetes close to the puberty, as observed in the 
later affected siblings, may increase the risk of severe DRP (201).  
10.2.5 OTHER POSSIBLE FACTORS INFLUENCING THE LONG-TERM 
PROGNOSIS WITHIN SIBSHIPS 
 
There are also other possible explanations for how early childhood could 
modify late diabetic complications. Very few chronic medical disorders of the 
childhood affect the young patients, their families, and their social networks 
as profoundly as type 1 diabetes. The treatment regimen often becomes a 
major source of stress for the family members and a potential focus of family 
conflicts (274). Parents that manage their child’s type 1 diabetes rate 
themselves as having stress, and those able to maintain their child’s 
glycaemic control indicate even higher levels of perceived stress (275). A high 
perceived stress could contribute to a less than optimal medical care of the 
siblings later affected with diabetes. A stressful family setting, such as a 
chronic physical problem in a close family member, has indeed been 
identified as a risk factor for poor glycaemic control (274, 276). This may be 
important in the long-term, since key social influences early in development 
may permanently change physiological stress reactivity patterns (277), and 
severe stress experienced in early life may have long-term consequences on 
adult physiological functions (278). Moreover, a poor glycaemic control 
during the first 5 years of diabetes has been observed to accelerate time to 
the occurrence of DRP (279). This may be related to the carry-over effect of 
prior glucose exposure, i.e. metabolic memory, which may be explained in 
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part by early glycation of proteins and AGE formation (280), or possibly by 
epigenetic phenomena (281, 282).  
10.3 AGE AT ONSET OF TYPE 1 DIABETES AS A 
MODIFIER OF RETINOPATHY PHENOTYPE 
10.3.1 EARLY AGE AT ONSET INCREASES RISK OF PDR IN A 
NONUNIFORM FASHION 
 
The risk of PDR was higher, if the age at onset of type 1 diabetes was less 
than 15 years. However, this risk increase was not uniform. There was an 
initially lower risk of PDR for the patients with the age at onset of type 1 
diabetes less than 5 years of age. In the long run, this initial advantage was 
lost (Fig. 17). The longest median duration to PDR was 22.2 (IQR 19.1-26.9) 
years in the 0-4 age at onset group (n= 79), whereas the shortest was 18.2 
(IQR 15.0-24.3) years in the 5-14 age at onset group (n= 212). In the 15-40 
group, the median duration to PDR was 20.0 (IQR 16.0-27.2) years (n= 76). 
The observation of longer duration to PDR in patients with the age at onset 
less than 5 years, is in line with earlier findings regarding DRP and 
nephropathy (198, 200, 283). The present study adds to this by showing that 
the long-term risk of PDR was no different between the age at onset groups 
of 0-4 years and 5-14 years despite the initial advantage for those with earlier 
onset of diabetes. Ultimately, the cumulative hazard curves for these two 
groups cross each other when the duration of diabetes approaches 30 years 
(Fig. 17).  
There are several reasons why the youngest patients may have a lower 
initial risk of PDR. The advantage for the youngest patients may be related to 
better self-care skills. It has been shown that a good self-care of diabetes 
correlates with good metabolic control (284). It may be easier to learn good 
self-care skills at a very young age as compared to the prepubertal period 
(283). Learning good self-care skills and adjusting to diabetes may be more 
difficult for prepubertal children as compared to the younger children which 
would explain the delayed onset of PDR in the youngest patients. The benefit 
of better glycaemic control may be compounded by a less steep decline in the 
endogenous insulin production. This is because a more stringent 
management of type 1 diabetes in children has been shown to reduce the 
decline in insulin production (285). In addition to factors related to learning 
and adjusting, hormonal changes in the puberty may contribute to an 
initially worse metabolic control in prepubertal children (286) and, at least, 
partially explain the initial difference in the risk of PDR. 
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10.3.2 LOWER RISK OF PDR IN PATIENTS WITH AGE AT ONSET 
AFTER 15 YEARS  
 
In contrast to the younger onset patients, the cumulative risk for PDR in 
those patients with the age at onset of type 1 diabetes between 15-40 years 
appears to be consistently lower. The onset of diabetes after the age of 12 
years has been associated with a lower risk of PDR in EURODIAB study as 
well (185). The lower risk may be due to the fact that the diabetes onset after 
puberty has been linked to a less aggressive form of type 1 diabetes (287), 
and it has also been observed that β-cells are better preserved when  type 1 
diabetes begins in adulthood (288). The better prognosis in older onset 
patients could, thus, be explained by the preservation of β-cells as the 
patients with later diabetes onset also had the highest C-peptide 
concentrations. The DCCT data has previously indicated that patients with 
any residual C-peptide secretion, but especially those with the highest 
stimulated concentrations, had a reduced incidence of DRP and nephropathy 
(204). However, the role of C-peptide has been somewhat controversial since 
it has not been linked to DRP in other studies (131). The association of age at 
onset with the risk of DRP may not only be limited to type 1 diabetes. It has 
been noted that a higher age at onset of diabetes reduces the risk of DRP in 
type 2 diabetes patients as well (203). 
10.3.3 LATER AGE AT ONSET OF TYPE 1 DIABETES INCREASES THE 
RISK OF MACULAR EDEMA 
 
In contrast to PDR, those patients with the age at onset of type 1 diabetes 
between ages 15-40 years may have a consistently higher risk of CSME than 
any patient group with the age at onset below 15 (Fig. 20). The patients with 
the highest age at onset had the highest cumulative incidence and risk of 
CSME, even when potential risk factors were taken into account. After 30 
years of diabetes, the cumulative incidences for CSME were 34% for the age 
at onset group of 15-40 years, 27% for the age onset group 5-14 years, and 
17% in those diagnosed between 0-4 years of age. The corresponding HRs 
were 3.72 and 1.89 as compared to the youngest (0-4 years) age at onset 
group.  
Because CSME is more common in older patients of whom many have 
type 2 diabetes, the goal of this study was initially to search for such features 
in patients with type 1 diabetes that could potentially explain why certain 
patients are more susceptible to CSME than others. It has indeed been shown 
in the FinnDiane study that it is possible for patients with type 1 diabetes to 
have features of type 2 diabetes as well (19, 289). An extensive statistical 
testing was, thus performed with typical features of type 2 diabetes as the 
primary suspects for CSME. About a hundred different statistical models 
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were tested with different combinations of various risk factors. These 
included eGDR (mg• kg-1•min-1), and triglycerides as surrogate markers for 
insulin resistance. The age of the patients was also included as well as the BP, 
BMI, and WHR. However the only associated risk factors, according to the 
strict BIC were the age at onset of type 1 diabetes, ETDRS-score, HbA1c, and 
total cholesterol. Prospective studies have shown an increased risk of DME if 
the baseline cholesterol is high (290). In the ETDRS study HbA1c and 
cholesterol were the only factors that predicted the development and 
persistence of severe visual loss due to PDR and DME (166). In this study, 
these two factors also produced the best fitting model which, thus, provides 
further support for the role of cholesterol as a risk factor for CSME. Other 
typical features of type 2 diabetes were less important as they were 
consistently more associated with a higher ETDRS score than CSME. This 
meant that the inclusion of these factors together with the ETDRS score 
deteriorated the fit of the regression equation and rendered them 
nonsignificant. 
10.3.4 NEPHROPATHY AND MACULAR EDEMA IN TYPE 1 DIABETES 
 
End-stage renal disease correlated strongly with the ETDRS score (rs = 0.64, 
P<0.001) and, probably because of this, it was not a significant risk factor for 
CSME if included in the model together with the ETDRS score (P=0.150, 
Wald test). The ETDRS score even overshadowed the BP in the model 
selection. The impact of diabetic nephropathy has not always been evident in 
previous studies either (108), although it has been noted that albuminuria is 
associated with DME (291), and that renal replacement therapy may stabilize 
the DRP status and reduce DME as a result of correction of overhydration 
(177). It is also known that microalbuminuria predicts the development of 
PDR in patients with type 1 diabetes (292). However, there is still some 
controversy whether this association is more due to hyperglycaemia or 
whether nephropathy is truly an independent predictor for DRP. It has been 
observed, though, that after renal transplantation or initiation of dialysis 
visual function stabilizes (178). The stabilization could also be due to other 
factors, such as lower BP during renal replacement therapy (177).  
10.3.5 AGING ITSELF MAY BE A MODIFIER OF PROLIFERATIVE 
RESPONSES 
 
Higher age of the patient could at least partially explain the difference in the 
responses to hyperglycaemia-induced cellular injury. Hyperglycaemia exerts 
its detrimental effects only after a certain period of hyperglycaemic exposure. 
The patients who have had an older age at onset of type 1 diabetes are older 
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when they have had a long enough hyperglycaemic exposure to cause 
significant cellular injury. Recent findings in research on ageing suggest that 
cellular senescence contributes to the development and progression of many 
disease states (293). The predominant ageing mechanism of mitotic tissues is 
thought to be due to the gradual accumulation of senescent cells. Senescent 
cells have undergone an irreversible cell cycle arrest as opposed to most 
mitotic cells that are found in a reversible growth arrested state known as 
quiescence. How often the quiescent cells proliferate is dependent upon how 
frequently cells become damaged or lost. The proliferative response to 
cellular injury is, thus, attenuated as a result of ageing (293). The 
immunological responses are also altered by the natural ageing process 
which leads to a gradual deterioration of the immune system (294). An 
attenuated proliferative response to intraocular cellular injury can be seen 
after cataract surgery where old age significantly decreases epithelial cell 
proliferation and posterior capsule opacification as compared to the younger 
patients (295). In a similar fashion, the age at onset of type 1 diabetes may 
determine the specific biological response to the hyperglycaemic cellular 
injury. The distinct significance of the age at onset as a risk factor for CSME 
is in line with previous studies showing a higher incidence of CSME in older 
patients with type 1 and, especially, with type 2 diabetes (130, 132, 140). In 
addition to cellular senescence, ageing and hypertension may also cause 
structural changes in the retinal vasculature (296), although the inclusion of 
BP  into the regression model did not improve the fit of the model. 
10.4 HbA1C VARIABILITY AS A RISK FACTOR FOR 
RETINOPATHY 
10.4.1 HbA1C VARIABILITY INCREASES RISK FOR RETINOPATHY 
REQUIRING LASER TREATMENT  
 
The need for laser treatment was higher in those patients who had the widest 
HbA1c variability. PDR is the most common indication for laser treatment in 
type 1 diabetes and a large HbA1c variability was associated with an increased 
risk of PDR. The five-year cumulative incidence estimates of laser treatment 
were 19.1% in the highest quartile of HbA1c variability as compared to 9.5% in 
the lowest quartile with 1.6 times higher adjusted risk of laser treatment. 
Analysis of the DCCT data has previously shown that HbA1c variability was 
associated with a three-step progression of DRP on the 12 step ETDRS scale 
(173). This study adds to that knowledge by showing that there may be 
clinically significant consequences from HbA1c variability, such as laser 
treatment and PDR. This is true even if the renal status was taken into 
account as a confounding factor in the statistical analyses. Unlike in the 
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DCCT, the results obtained in this study reflect a normal clinical setting 
without any confounding interventions on the HbA1c. 
10.4.2 HbA1C VARIABILITY AND POSSIBLE CONFOUNDING FACTORS 
 
Although there was an association between laser treatment, PDR, and HbA1c 
variability, it still remains to be seen whether HbA1c variability truly causes 
the DRP to progress. There may be confounding factors that explain the 
association between HbA1c variability and DRP progression. One such factor 
may be insulin resistance which is associated with HbA1c variability and has 
been implicated in the pathogenesis of diabetic complications (297). Higher 
triglycerides were noted in those patients who were in the highest quartile of 
HbA1c variability. This supports the possible association with insulin 
resistance although the inclusion of triglycerides in the models did not 
change the overall significance of HbA1c variability in either subcohort. 
Another  possible mechanism may be the exponential fashion by which both 
higher mean HbA1c and higher HbA1c variability increases the risk of 
microvascular complications (173). Thus, even short periods of higher HbA1c 
could significantly increase the risk of PDR, even in the presence of 
comparable mean HbA1c levels. However, the inclusion of first and second 
order interaction terms in the regression models to account for the 
exponential risk that increased with higher mean HbA1c and higher HbA1c 
variability did not change the results in Fine & Gray regression models. 
Furthermore, the ETDRS score and the mean HbA1c did not show any 
exponential relationship which suggests that other mechanisms are also 
likely to play a role.  
The present study may be biased by the fact that the serial HbA1c values 
were collected from available laboratory records as part of the patients’ 
routine clinical follow-ups. Thus, there were no prespecified intervals 
between the HbA1c measurements, and also the number of measurements per 
individual patient varied. Another potential limitation is the use of HbA1c 
measured at the local study centres, not in a central laboratory. However, the 
individual patient’s measurements were performed at the same centre and 
the Fine &  Gray regression models accounted for the possible correlations 
within the participating study centres. The regression models were adjusted 
for both the number of HbA1c measurements and the mean HbA1c. Moreover, 
the standardisation of the HbA1c measurement intervals to one year by 
resampling of the original measurements retained the significance for 
variability quartiles as risk factor for both PDR and laser treatment. 
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10.4.3 HbA1C VARIABILITY AND PATHOGENESIS OF DIABETIC 
RETINOPATHY 
 
A possible impact of HbA1c fluctuation itself is supported by the fact that a 
short term DRP worsening has been observed in patients with improved 
glycaemic control. This has been shown in many studies (157, 167-171). 
Interestingly, the short term glucose fluctuations do not appear to increase 
the risk of DRP progression (298). The difference could be related to 
“metabolic memory” in which periods of even short hyperglycaemia place 
patients at higher risk (159).    
Another potential explanation for this discrepancy is the intermittent, 
more intensive use of insulin. Insulin induces the expression of VEGF and 
together with stabilized HIF-1α may explain the initial worsening of DRP 
which is observed in improved glycaemic control (103, 104). Repeated cycles 
of intensive insulin use could, therefore, result in a sustained DRP 
progression. There are, however, many other possible cellular mechanisms 
that may be involved, such as the induction of growth factor IGF-1 (299, 300) 
and impaired endothelial function (301). Other detrimental in vitro cellular 
effects due to oscillating glucose have been noted as well (302-304).  
10.4.4 AGE AT ONSET AND LESS VARIABLE HbA1C 
 
A possible factor behind a less variable HbA1c may be the age at onset. The 
patients with a higher age at onset had less variable HbA1c measurements. As 
noted before, the β-cells are better preserved when type 1 diabetes begins in 
adulthood  (288). The DCCT data indicated that patients with any residual C-
peptide secretion had a reduced incidence of DRP and nephropathy (204). 
Thus, the preservation of β-cells could explain the connection between a 
lower risk of PDR and less variable HbA1c measurements. The patients with 
PDR in the present study had the lowest C-peptides which supports this 
hypothesis. 
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11 SUMMARY AND CONCLUSIONS  
I. PDR in type 1 diabetes showed familial clustering which could not be 
accounted for by conventional risk factors. If the oldest sibling in the 
sibship had PDR, the risk for all the subsequent siblings increased. 
The heritability estimate suggests the presence of a multifactorial 
familial component in the development of PDR. 
 
II. The age at onset of type 1 diabetes modified the risk of PDR. The 
patients diagnosed with type 1 diabetes before 15 years of age had a 
higher risk of PDR than patients diagnosed after 15 years of age. 
 
III. A wide HbA1c variability increased the risk of severe retinopathy 
requiring laser treatment. The patients in the highest quartile of HbA1c 
variability had a 1.6 times higher adjusted risk as compared to patients 
in the lowest quartile.  
 
IV. There was a significant association between the age at onset of type 1 
diabetes and the risk of CSME. The higher the age at onset of type 1 
diabetes, the higher the risk of CSME. This observation could not be 
explained by risk factors associated with old age or features typical of 
type 2 diabetes. This indicates a potential role for the biological 
changes related to ageing itself in determining the DRP phenotype. 
 
V. The siblings first affected by type 1 diabetes were younger than the 
later affected siblings. The first affected siblings had a lower risk of 
PDR which was most likely related to their longer prepubertal 
diabetes duration.  
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THE FINNISH DIABETIC NEPHROPATHY STUDY CENTERS 
Anjalankoski Health Center S.Koivula, T.Uggeldahl 
Central Hospital of Central Finland, Jyväskylä  T. Forslund, A.Halonen, 
A.Koistinen, P.Koskiaho 
M.Laukkanen, J.Saltevo, 
M.Tiihonen 
Central Hospital of Åland Islands, Mariehamn  M.Forsen, H.Granlund, A.-
C.Jonsson, B.Nyroos 
Central Hospital of Kanta-Häme, Hämeenlinna  P.Kinnunen, A.Orvola, 
A.Vähänen 
Central Hospital of Kymenlaakso, Kotka  R.Paldanius, M.Riihelä, L.Ryysy 
Central Hospital of Länsi-Pohja, Kemi  H.Laukkanen, P.Nyländen, 
A.Sademies 
Central Hospital of Ostrobothnia, Kokkola  S.Anderson, B.Asplund, 
U.Byskata, P.Liedes,
M.Kuusela, T.Virkkala 
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Espoonlahti  A.Nikkola, E.Ritola 
Tapiola  M.Niska, H.Saarinen 
Samaria  E.Oukko-Ruponen, T.Virtanen 
Viherlaakso  A.Lyytinen 
City of Helsinki Health Centers: 
Puistola  H.Kari, T.Simonen 
Suutarila  A.Kaprio, J.Kärkkäinen, 
B.Rantaeskola 
Töölö  P.Kääriäinen, J.Haaga,   
A-L.Pietiläinen 
City of Hyvinkää Health Center  S.Klemetti, T.Nyandoto, 
E.Rontu, S.Satuli-Autere 
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Korso  R.Toivonen, H.Virtanen 
Länsimäki  R.Ahonen, M.Ivaska-Suomela, 
A.Jauhiainen 
Martinlaakso  M.Laine, T.Pellonpää, 
R.Puranen 
Myyrmäki  A.Airas, J.Laakso, K.Rautavaara 
Rekola  M.Erola, E.Jatkola 
Tikkurila  R.Lönnblad, A.Malm, J.Mäkelä, 
E.Rautamo 
Heinola Health Center  P.Hentunen, J.Lagerstam 
Helsinki University Central Hospital,  
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K.Hietala, J.Kytö, S.Lindh,  
K.Pettersson-Fernholm, 
A.Sandelin, L.Thorn, 
J.Tuomikangas, T.Vesisenaho, 
J.Wadén 
Herttoniemi Hospital, Helsinki  V.Sipilä 
Hospital of Lounais-Häme, Forssa  T.Kalliomäki, J.Koskelainen, 
R.Nikkanen, N.Savolainen, 
H.Sulonen, E.Valtonen 
Hyvinkää Hospital L. Norvio, A. Hämäläinen 
Iisalmi Hospital  E.Toivanen 
Jokilaakso Hospital, Jämsä  A.Parta, I.Pirttiniemi 
Jorvi Hospital,  Espoo  S.Aranko, S.Ervasti, 
R.Kauppinen-Mäkelin, 
 A.Kuusisto, T.Leppälä, 
K.Nikkilä, L.Pekkonen 
Jyväskylä Health Center, Kyllö  K.Nuorva, M.Tiihonen 
Kainuu Central Hospital, Kajaani  S.Jokelainen, K.Kananen, 
M.Karjalainen, P.Kemppainen, 
A-M.Mankinen, A.Reponen 
 M.Sankari 
Kerava Health Center  H.Stuckey, P.Suominen 
Kirkkonummi Health Center  A.Lappalainen, M.Liimatainen, 
J.Santaholma 
Kivelä Hospital, Helsinki  A.Aimolahti, E.Huovinen 
Koskela Hospital, Helsinki  V.Ilkka, M.Lehtimäki 
Kotka Health Center  E.Pälikkö-Kontinen, 
A.Vanhanen 
Kouvola Health Center  E.Koskinen, T.Siitonen 
Kuopio University Hospital E.Huttunen, R.Ikäheimo, 
P.Karhapää, P.Kekäläinen, 
 M.Laakso, T.Lakka, 
E.Lampainen, L.Moilanen, 
 L.Niskanen, U.Tuovinen, 
I.Vauhkonen, E.Voutilainen 
Kuusamo Health Center  T.Kääriäinen, E.Isopoussu 
Kuusankoski Hospital  E.Kilkki, I.Koskinen, L.Riihelä 
Laakso Hospital, Helsinki  T.Meriläinen, P.Poukka, 
R.Savolainen, N.Uhlenius 
Lahti City Hospital  A.Mäkelä, M.Tanner 
Lapland Central Hospital, Rovaniemi  L.Hyvärinen, K.Lampela, 
S.Pöykkö, T.Rompasaari, 
S.Severinkangas, T.Tulokas 
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Lappeenranta Health Center  P. Erola, L. Härkönen, 
P.Linkola, I.Pulli, E.Repo  
Lohja Hospital  T.Granlund, K.Hietanen, 
M.Porrassalmi, M.Saari, 
T.Salonen, M.Tiikkainen,  
Länsi-Uusimaa Hospital, Tammisaari  I.-M.Jousmaa, J.Rinne 
Loimaa Health Center  A.Mäkelä, P.Eloranta 
Malmi Hospital, Helsinki  H.Lanki, S.Moilanen, M.Tilly-
Kiesi 
Mikkeli Central Hospital  A.Gynther, R.Manninen, 
P.Nironen, M.Salminen, 
 T.Vänttinen 
Mänttä Regional Hospital  I.Pirttiniemi, A-M.Hänninen 
North Karelian Hospital, Joensuu  U-M.Henttula, P.Kekäläinen, 
M.Pietarinen, A.Rissanen, 
M.Voutilainen 
Nurmijärvi Health Center  A.Burgos, K.Urtamo 
Oulaskangas Hospital, Oulainen  E.Jokelainen, P-L.Jylkkä, 
E.Kaarlela, J.Vuolaspuro 
Oulu Health Center  L.Hiltunen, R.Häkkinen, 
S.Keinänen-Kiukaanniemi 
Oulu University Hospital  R.Ikäheimo 
Päijät-Häme Central Hospital  H.Haapamäki, A.Helanterä, 
S.Hämäläinen, V.Ilvesmäki, 
H.Miettinen 
Palokka Health Center  P.Sopanen, L.Welling 
Pieksämäki Hospital  V.Sevtsenko, M.Tamminen 
Pietarsaari Hospital  M-L.Holmbäck, B.Isomaa, 
L.Sarelin 
Pori City Hospital  P.Ahonen, P.Merisalo, 
E.Muurinen, K.Sävelä 
Porvoo Hospital  M.Kallio, B.Rask, S.Rämö 
Raahe Hospital  A.Holma, M.Honkala, 
A.Tuomivaara, R.Vainionpää 
Rauma Hospital  K.Laine, K.Saarinen, 
T.Salminen 
Riihimäki Hospital  P.Aalto, E.Immonen, 
L.Juurinen 
Salo Hospital  A.Alanko, J.Lapinleimu, 
P.Rautio, M.Virtanen 
Satakunta Central Hospital, Pori  M.Asola, M.Juhola, P.Kunelius, 
M.-L.Lahdenmäki, 
 P.Pääkkönen, M.Rautavirta 
Savonlinna Central Hospital  T.Pulli, P.Sallinen, M.Taskinen, 
E.Tolvanen, T.Tuominen 
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 H.Valtonen, A.Vartia, S-
L.Viitanen 
Seinäjoki Central Hospital  E.Korpi-Hyövälti, T.Latvala, 
E.Leijala 
South Karelia Central Hospital, Lappeenranta  T.Ensala, E.Hussi, 
R.Härkönen, U.Nyholm, 
J.Toivanen 
Tampere Health Center A.Vaden, P.Alarotu, 
E.Kujansuu, H.Kirkkopelto-
Jokinen, M.Helin, 
S.Gummerus, L.Calonius, 
T.Niskanen, T.Kaitala,  
 T.Vatanen 
Tampere University Hospital I.Ala-Houhala, R.Kannisto, 
T.Kuningas, P.Lampinen, 
M.Määttä, H.Oksala, 
T.Oksanen, A.Putila, H.Saha, 
K.Salonen, H.Tauriainen, 
 S.Tulokas 
Tiirismaa Health Center, Hollola  T.Kivelä, L.Petlin, L.Savolainen 
Turku Health Center  A.Artukka, I.Hämäläinen, 
L.Lehtinen, E.Pyysalo, 
H.Virtamo, M.Viinikkala, 
M.Vähätalo 
Turku University Central Hospital  K.Breitholz, R.Eskola, 
K.Metsärinne, U.Pietilä, 
 P.Saarinen, R.Tuominen, 
S.Äyräpää 
Vaajakoski Health Center  K.Mäkinen, P.Sopanen 
Valkeakoski Regional Hospital  S.Ojanen, E.Valtonen, 
H.Ylönen, M.Rautiainen, 
 T.Immonen 
Vammala Regional Hospital  I.Isomäki, R.Kroneld, 
L.Mustaniemi, M.Tapiolinna-
Mäkelä 
Vasa Central Hospital  S.Bergkulla, U.Hautamäki, V-
A.Myllyniemi, I.Rusk 
 
